EXPERIENCE WITH PRESCRIPTIVE AUTHORITY SERVICES AMONG COMMUNITY PHARMACISTS IN SASKATCHEWAN by Jain, Rahul
   
 
EXPERIENCE WITH PRESCRIPTIVE AUTHORITY SERVICES AMONG 
COMMUNITY PHARMACISTS IN SASKATCHEWAN 
 
 
A Thesis Submitted to the College of 
Graduate Studies and Research 
In Partial Fulfillment of the Requirements 
For the Degree of Master of Science 
In the College of Pharmacy and Nutrition 
Division of Pharmacy 
University of Saskatchewan 
Saskatoon 
 
By 
Rahul Jain 
 
 
© Copyright Rahul Jain, November 2015. All rights reserved 
  
 
i 
 
PERMISSION TO USE 
In presenting this dissertation in partial fulfilment of the requirements for a postgraduate 
degree from the University of Saskatchewan, I agree that the Libraries of this University may 
make it freely available for inspection. I further agree that permission for copying of this thesis 
in any manner, in whole or in part, for scholarly purposes may be granted by the professor or 
professors who supervised my thesis work or, in their absence, by the Assistant Dean or the Dean 
of the College in which my thesis work was done. It is understood that any copying, publication, 
or use of this thesis or parts thereof for financial gain shall not be allowed without my written 
permission. It is also understood that due recognition shall be given to me and to the University 
of Saskatchewan in any scholarly use which may be made of any materials in my dissertation. 
 
Requests for permission to copy or to make other use of material in this thesis in whole or part 
should be addressed to: 
Assistant Dean Pharmacy,  
College of Pharmacy & Nutrition 
University of Saskatchewan 
Saskatoon, Saskatchewan S7N 2Z4 
Canada 
 
 
 
 
 
 
 
 
ii 
 
ABSTRACT 
In recent years, a significant change in the pharmacist’s scope of practice is the expansion of 
prescriptive authority (PA). In Saskatchewan, pharmacists adopted an interdependent prescribing 
model to support interprofessional collaboration, public safety though the optimal use of drug 
therapy, and the optimization of pharmacy competencies. In acquiring this new prescriptive 
authority, the community pharmacist also assumes new responsibilities and obligations, as well 
as transforming their relationships with patients and physicians.  
The purpose of this research is to assess rates of adoption by pharmacists of PA (Level 1 
and Minor Ailments Prescribing) within community pharmacy practice in Saskatchewan. To gain 
a better understanding of how pharmacists are responding to new and evolving models of 
practice, this study proposes to measure their experiences with PA services and how it is affected 
by aspects of their professional practice.   
To investigate the study’s research questions, a cross-sectional study using a mail-in 
questionnaire with an online option was initiated. All registered community pharmacists in 
Saskatchewan (998) were asked to participate in the study. Of the 998 distributed questionnaires, 
501 were returned back by the respondents yielding a response rate of 51.3 percent.  
The results disclose that a vast majority of respondents agreed or strongly agreed that 
they were confident in their ability to provide Level 1 (94%) and Minor Ailment (75%) 
prescribing. Respondents indicated that 74.2 percent of the time they actually provide Level 1 
(L1) prescribing services to their patients and slightly more than half (52.5%) of the time 
provided Minor Ailment (MA) prescribing services. The majority of respondents (81.4 %) 
indicated that on average it took twenty minutes or less to provide MA prescribing service to 
their patients.  
Most pharmacist respondents strongly supported the statement that the pharmacies they 
worked at consistently provided Prescriptive Authority services (L1- 90% Strongly Agreed or 
Agreed, MA- 52.9% Strongly Agreed or Agreed) and that they get full support from managers 
(L1- 95.6% Strongly Agreed or Agreed, MA- 88% Strongly Agreed or Agreed) for their 
involvement in PA services.  
Respondents indicated some concern regarding the limited knowledge of patients on what 
pharmacists can do for them as a prescriber. In terms of overall relationships with patients, 
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respondents indicated that patients were satisfied with the services pharmacists provide as a 
prescriber.  
Respondents reported that they had a good relationship with physicians. However, they 
did express concerns about their limited interactions with physicians as MA prescribers. 
Respondents generally reported supportive environments and positive interactions with 
patients and physicians. However, while expressing confidence in their ability to provide all 
prescriptive authority services, Level 1 services that supported traditional dispensing services 
were generally more consistently provided, supported, and perceived as being valued by patients 
and physicians compared to Minor Ailment Prescribing. 
The results also support the notion that pharmacists are highly confident to provide PA 
services to the patients and their relationships with the patients and physician improved day by 
day. Nevertheless, there is little evidence to suggest that patient’s level of knowledge about 
pharmacist’s new role; pharmacist’s interaction with physicians and physicians’ knowledge on 
PA have affected the provision of Prescriptive Authority services. 
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1. INTRODUCTION 
Pharmacists have been described as well trained and highly educated health care 
professionals with richly developed clinical judgment and scientific skills unique from other 
health professionals (Weiss & Sutton, 2009); although their expertise is seen as chronically 
under-utilized, their involvement in clinical activities has steadily increased in recent years. 
Pharmacists now provide multiple levels of direct and indirect patient care services in a variety 
of practice settings; to more effectively manage the care of their patients, pharmacists 
increasingly: carry out patient assessment; order, interpret, and monitor laboratory tests; create 
and implement therapeutic plans; and provide ongoing and follow‐up care (Giberson, Yoder, & 
Lee, 2011). The nature of pharmacy practice is also evolving with changes in the authority and 
responsibilities of pharmacists. Pharmacists are taking on a greater role in prescribing and 
managing medication in the provision of quality patient care through improved drug selection, 
dosing, use and monitoring (Law, Ma, Fisher, & Sketris, 2012). 
2. LITERATURE REVIEW 
The literature review begins with an overview of the evolution of the practice 
internationally and in Canada, followed by a review of the prescriptive authority of pharmacists 
including the continuous progress in the pharmacist’s scope of practice. This is followed by a 
review of generally-accepted prescriptive authority models with a focus on Canadian models; 
and in particular the Saskatchewan model. 
 The next section reviews a recent and major addition to the pharmacist’s scope of 
practice (Minor Ailment Prescribing). This briefly summarizes the minor ailment conditions that 
pharmacists are eligible to assess and the guideline they need to follow. This is followed by a 
review of some challenges that pharmacists face while performing prescriptive authority 
services. 
Next, the impact of prescriptive authority services on the relationships of a pharmacist 
with physicians and patients is focused on. This literature review is concluded with a brief 
summary of the concerns discussed, followed by research questions and hypotheses. 
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2.1  The Evolution of Pharmacy Practice 
Prior to the mid-1950s, pharmacists had a well-defined social value centered on the 
manufacturing and distribution of drug products (Holland & Nimmo, 1999); however, the role of 
the community pharmacist was generally limited to the compounding, dispensing and labeling of 
pharmaceutical products for their patients (Pearson, 2007; Adamcik, et al, 1986). By the mid-
1960s, with the emergence of the concept of clinical pharmacy, pharmacists began to move 
toward a more patient oriented practice.  By the early 1980s, emerging technologies allowed 
pharmacists to develop better communication with their patients resulting in improved 
compliance with drug therapies (McBean & Blackburn, 1982; Hurd et al, 1984). 
In the 1990s, the pharmaceutical care model emerged which emphasized the role of the 
pharmacist in the responsible provision of drug therapy for the purpose of achieving definite 
outcomes that improve a patient’s quality of life (Pearson, 2007; Hepler & Strand, 1989; CPhA, 
September 2008). Today, pharmacists are seeking to be patient-centered health care providers, 
educated to respond to, provide advice on and/or fulfill many of their patients’ health care as 
well as drug-related needs.  
While often perceived as medication dispensers, pharmacists’ professional roles now go 
well beyond that function.  Generally perceived as the most accessible health care professionals, 
pharmacists are also seen as increasingly important members of the health care team (CPhA, 
2011; Carey, 2010; Lai et al, 2013). Presently, their role in addition to expanding scopes of 
practice, pharmacy is seen as one of the most trusted professions (C-Health News, Sept 30, 
2014).  
According to Lai et al (2013) cooperation between pharmacists and other health care 
providers has also improved with the expansion of the pharmacist role in healthcare and patient 
care. Studies have also shown that physicians have accepted that it is important to expand the 
community pharmacist’s role in patient advocacy to help provide patients with medical 
information (Lai et al, 2013; Bradshaw & Doucette, 1998). 
As the health system’s drug experts, pharmacists have been involved or have the potential 
to be involved in providing many health care services (Carey, 2010; Lai et al, 2013). These 
services may include, but are not restricted to:  
 Formulate and execute treatment plans;  
 Select, initiate, modify, or administer drug therapy;  
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 Monitor and evaluate the patient’s reaction, including effectiveness and safety;  
 Medication and disease education in order to improve understanding and 
appropriate use of medications;  
 Provide necessary information to the patient’s health care team;  
 Promote patient adherence; provide information and education on over-the-
counter products, natural health products and procedures for various minor 
ailments; 
 Coordinate and integrate medication therapy management (MTM) services  
2.2 Prescriptive authority (the next step in the evolution of pharmacy practice) 
One of the more significant changes in scopes of practice in the last 10 years is the 
expansion of prescriptive authority to a number of health professions, including pharmacy 
(Cooper et al., 2008). The rationale for expanding prescribing authority to other healthcare 
professionals is to enhance the continuity of care and patients’ access to medicines, while 
reducing waiting times and fragmentation of care (Cooper et al., 2008). 
Prescriptive authority is defined as the legal recognition by federal, state or provincial 
law that an individual is entitled to recommend the initiation, modification and discontinuance of 
the drug treatment for other than him or herself (Yuvs et al., 2000). Globally, many healthcare 
systems such as the United Kingdom, Australia and the USA include some form of prescribing 
(e.g. renew/extend prescription and prescribing in emergency) by pharmacists or other non-
physician healthcare professionals, offering potential advantages in terms of increasing patients’ 
continuity of care and access to medicines, better utilization of economic and human resources, 
reductions in patient waiting times and less fragmentation of care (Cooper et al. 2008.; Nissen, 
L., 2011).   
The role of the pharmacist in prescribing medications has taken many turns throughout 
history (Lloyd et al., 2010).  In the more traditional model of prescribing, physicians have the 
authority to prescribe medication, order laboratory tests and perform procedures consistent with 
a patient’s diagnosis (Pearson et al., 2001).  In more recent scenarios, prescriptive authority has 
extended to other health professions. The rationale for extending prescriptive authority include: 
decreasing general practitioners workload; improving patient access to medication; maintaining 
continuity of patient care; optimizing medication management; and using pharmacists to their 
full scope of practice (Emmerton et al., 2005; Pharmacist Prescribing, 2010).  
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To improve patient access to medicines, quality of prescribing, and patient monitoring, 
limited prescribing privileges have been extended to pharmacists in some jurisdictions.  The 
rationale for giving pharmacists this authority is that they are the profession with the most 
education and experience in drug therapy and that they are highly trained in the appropriate 
selection and management of prescription medications (Law et al., 2012).   
2.3  Prescriptive Authority Models 
The ability of pharmacists to “prescribe” in a community setting has increased 
considerably in recent years; however, the nature of prescribing varies across jurisdictions (Law 
et al., 2012). In Canada, Alberta was the first province to initiate some form of prescribing by 
pharmacists in 2007 (Yuksel et al., 2008; Mansell et al., 2014). After that, other Canadian 
provinces and territories started giving some form of prescribing rights to the pharmacists 
(CPhA, 2013; Mansell et al., 2014).  
2.3.1  Pharmacist Prescriber Models 
In general, pharmacist prescribing models are broadly categorized as one of two types. 
The first is dependent or supplementary prescribing and the second is independent prescribing 
(Emmerton et al., 2005). 
Dependent Prescribing: Under the dependent prescribing (DP) model the pharmacist is 
not completely responsible for patient’s evaluation and health care assessment. In this model, the 
physician (also referred to as primary prescriber) and the pharmacist (also referred to as the 
supplementary prescriber) work on the basis of mutual partnership and agree to assess patients 
according to a defined protocol; often either pre-written guidelines or a formulary containing a 
detailed list of activities that the pharmacist will perform (Emmerton L. et al. 2005).  
Independent prescribing: Under the independent prescribing model, the pharmacist is 
entirely responsible for patient evaluation and health care assessment.  In addition, the 
pharmacist must be able to fulfill some/all of the following criteria to prescribe as an 
independent prescriber (PIP, General Pharmaceutical Council, 2006): 
 Understand the responsibilities that the role of independent prescriber entails, be aware of 
their own limitations, and work within the limits of their professional competence; 
 Develop an effective relationship and communication with patients, careers, other 
prescribers and members of the health care team; 
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 Describe the pathophysiology of the condition being treated and recognize the signs and 
symptoms of illness take an accurate history and carry out a relevant clinical assessment 
where necessary;   
 Able to use diagnostic aids relevant to the condition(s) for which the pharmacist intends 
to prescribe, including monitoring response to therapy; 
 Demonstrate a shared approach to decision making by assessing patients’ needs for 
medicines, taking account of their wishes and values and those of their care providers 
when making prescribing decisions;  
 Demonstrate an understanding of the public health issues related to medicines use.  
 Demonstrate an understanding of the legal, ethical and professional framework for 
accountability and responsibility in relation to prescribing; and  
 Work within clinical governance frameworks that include audit of prescribing practice 
and personal development. 
In the United Kingdom, pharmacists have been able to train and practice as prescribers 
since 2003, initially as supplementary (2003) and later (2006) the independent prescribers 
(Cooper et al. 2008; Stewart et al. 2010). Within independent prescribing, pharmacists are 
eligible to prescribe all the medications that come under their capabilities except controlled drugs 
(Cooper et al. 2008; Tonna et al. 2007; Reeves, 2007). Apart from supplementary and 
independent prescribing, pharmacists in the UK are also eligible to get into some other 
prescribing activities such as: Formulary Prescribing (FP), Patient Referral (PR) and Patient 
Group Directives (PGD) (Emmerton et al., 2005).  
In the United States, at least 45 states allow limited pharmacist dependent prescribing as 
part of collaborative drug therapy management (CDTM) agreements (Pearson, 2007; Pharmacist 
prescribing task force, information paper, May-June 2010; Traynor, 2004; Meyer, et al. 2008; 
Status CTDM, 2004;). The way this model works is the doctor must first diagnose the medical 
condition and then the pharmacist selects the proper medication for the diagnosed condition, 
initiates, monitors, modifies and discontinues the drug therapy if required (Emmerton et al. 2005; 
Hammond et al. 2003; Hoti et al. 2011) . Three US states (New Mexico, North Carolina and 
Montana) allow pharmacists to initiate drug therapy (Pharmacist prescribing task force, 
information paper, May-June 2010).  
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2.3.2  Canadian Models 
 In Canada, many provinces have substantially broadened the pharmacist’s right to 
prescribe and the profession’s scope of practice over the past few years.  For example, 11 out of 
thirteen provinces/territories in Canada allow pharmacists to prescribe independently to some 
degree (Table 2.1) (Law et al., 2012).  
Table 2.1: Pharmacists' Expanded Scope of Practice Activities across Canada 
Canadian Pharmacists Association. June 2015 
In all 10 provinces and 1 territory, pharmacists are allowed to continue existing 
prescriptions and emergency prescription refills, ten allow changes to drug dosage or 
formulation, eight allow pharmacists to make therapeutic substitution, seven provinces allow 
pharmacists to prescribe for minor illness, eight allow pharmacists to initiate prescription drug 
 Implemented in 
Jurisdiction 
 
 
Province/Territory 
  Pending 
Legislation 
 
× Not Implemented 
 
BC AB SK MB ON QC NB NS PEI NL NWT YT NU 
P
h
a
rm
a
ci
st
 S
co
p
e 
o
f 
P
r
a
ct
ic
e
 
Provide emergency 
prescription refills 
 
           × × 
Renew/extend 
prescriptions 
 
           × × 
Change drug 
dosage/formulation 
 
          × × × 
Make therapeutic 
substitution 
 
   × ×      × × × 
Minor ailments 
prescribing 
 
×    ×       × × × 
Initiate 
prescription drug 
therapy 
 
×         × × × × 
Order and interpret 
lab tests 
 
×         × × × × 
Administer a drug 
by injection 
 
     ×     × × × 
Regulated Pharmacy 
Technicians 
     ×     × × × 
 BC AB SK MB ON QC NB NS PEI NL NWT YT NU 
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therapy, eight province allow pharmacists to administer a drug by injection and seven provinces 
allow pharmacists to regulate pharmacy technicians. Only four provinces allow pharmacists to 
order and interpret lab tests (Law et al., 2012). 
2.4 Interdependent prescribing (the Saskatchewan model)  
In 2006, the Saskatchewan College of Pharmacists proposed an interdependent 
prescriptive authority model to optimize the role of pharmacists in collaborative prescribing, to 
improve the primary health care system and to promote the mutual bonding between patients, 
pharmacists, physicians and nurses (SCP, 2006).  In this model, the pharmacist relies upon the 
diagnostic skills of the physician and the assessment skills of nurses, who in turn rely upon the 
drug therapy knowledge of pharmacist.  Working collaboratively, their ultimate goal is to 
optimally manage the pharmacotherapy of patients and ensure optimal health outcomes
 
(SCP, 
2006). 
For the profession, the fundamental objectives behind introducing the interdependent 
prescriptive model in Saskatchewan were to: broaden the pharmacist’s scope of practice; allow 
pharmacists to recommend drugs within current competencies; expand the authority of the 
pharmacist to recommend medication; optimize the role of pharmacist; legalize activities that the 
pharmacist is skilled in performing; and assist the physician and other distinct health care 
providers in administrating pharmacotherapy to patients (SCP, 2006).   
 Under this model (SCP, 2006) pharmacists are allowed to prescribe medication for:   
• Continuing therapy – interim supplies and maintenance 
• Previously prescribed drugs in emergency situations 
• Incomplete or inaccurate prescriptions 
• Refills during physician’s absence 
• Medications to be continued when moving from one setting in the health care 
system to another 
• Self-care of minor ailments where a prescription drug is more effective 
However, the pharmacist is not authorized to prescribe narcotics, controlled drugs and targeted 
substances (SCP, 2006).  
2.5 Minor ailment prescribing: expansion of prescriptive authority in SK 
All community pharmacists licensed to practice in Saskatchewan are required to 
complete “Prescriptive Authority Level 1 - basics” and “Minor Ailments Training” (MedSask, 
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2015).  Minor Ailment Prescribing is a Level I Prescriptive Authority service in which patients 
are able to seek the help of their community pharmacist if they need prescription medications for 
certain minor ailments or self-diagnosed conditions.  
In minor ailment prescribing, if the self-diagnosis is good enough based on the 
pharmacist’s assessment and the suitable treatment option in the pharmacist’s judgment is a 
Schedule 1 drug, the pharmacist is eligible to initiate a prescription (MedSask, 2015). If the 
pharmacist is unable to confirm the patient’s diagnosis or the patient’s symptoms are severe, the 
pharmacist is required to refer the patient to a physician or other appropriate health care provider. 
By May 2012, the Saskatchewan College of Pharmacists Council for Minor Ailment 
Services had given prescriptive authority for pharmacists to assess and prescribe Schedule 1 
drugs for several minor ailment conditions including mild acne, allergic rhinitis, cold sores, 
diaper dermatitis, insect bites, simple mouth ulcers, and oral thrush (Table 2.2) (MedSask, 2015).   
Table 2.2: Minor Ailment Conditions in 2012 
 Minor Ailments Conditions Added to the list 
1 Mild acne  
Feb 1
st
, 2012 2 Cold sores 
3 Insect bites 
4 Diaper dermatitis,   
May 24
th
, 2012 5 Simple mouth ulcers 
6 Oral thrush 
7 Allergic rhinitis 
Saskatchewan College of Pharmacists (SCP), July 2014; MedSask, 2015 
In addition, Saskatchewan pharmacists broke new ground in Canada with minor ailment 
assessment fees effective from February 1, 2012.  These fees provide pharmacies with $18 per 
intervention when they assess approved “minor ailment conditions” that result in a prescription 
with medication (Lynas, 2012). 
More recently, SCP Council approved the addition of new minor ailments conditions  
including headache and migraine, bacterial skin infections, atopic dermatitis, dyspepsia, GERD 
(Gastroesophageal Reflux Disease ) and tinea infections (such as athlete’s foot and ringworm), 
hemorrhoids, dysmenorrhea, and muscular skeletal pain, spasm and stiffness (Table 2.3) 
(MedSask, 2015). 
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Table 2.3: Minor Ailment Conditions in 2014 
 Minor Ailments Conditions Added to the list 
1 Headache and Migraine  
 
 
 
July 29
th
, 2014 
2 Bacterial skin infections 
3 Atopic dermatitis 
4 Dyspepsia 
5 GERD  
6 Tinea infections (such as athlete’s foot and 
ringworm)  
7 Hemorrhoids 
8 Dysmenorrhea 
9 Muscular skeletal pain, spasm and stiffness 
Saskatchewan College of Pharmacists (SCP), July 2014; MedSask, 2015 
 Guidelines for each minor ailment were developed by Saskatchewan Drug Information 
Services (SDIS) (now MedSask). Pharmacists are required to follow the given guideline while 
assessing patients for minor ailments. All pertinent information related to the minor ailments is 
contained in the individual guidelines including: overview of pathophysiology; common signs 
and symptoms; patient assessment and treatment for each condition; how to assess; and when to 
refer (MedSask, 2015).  
The expansion of pharmacist’s scope of practice into minor ailment prescribing was 
designated to allow pharmacists to better fulfill their patients' health care related needs. The 
stated purpose was to allow pharmacists to more effectively encourage patients to make 
decisions regarding their health by consulting a pharmacist so that they can take care of their 
health in an optimal manner, not only in cities but, in rural and remote areas as well 
(Government of Saskatchewan, 2012). 
Pharmacists are seen as well prepared and skilled to have an important and positive 
impact on patient health in Saskatchewan. According to public opinion polls, Saskatchewan 
residents are not only happy with pharmacists providing minor ailment prescribing services, they 
also need pharmacists to provide many other health related services so that patients can get more 
benefits (Government of Saskatchewan, 2012).  
2.6 Prescriptive Authority: Challenges 
 Prescriptive authority represents an expansion of scope of practice for most community 
pharmacists in Saskatchewan. In expanding their scopes of practice, pharmacists will be required 
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to change the nature of their work. As pharmacists seek to redefine their work activities to 
accommodate prescriptive authority, they may also face challenges due to existing structures and 
processes within their current practice settings. 
While the expansion of prescriptive authority represents a significant opportunity for 
pharmacists to enhance their role in the delivery of quality patient care services, a number of 
challenges within the practice environment have the potential to limit the ability of pharmacists 
to fully adopt an expanded clinical role in the care of their patients.  These challenges include: 
workload and time constraints; clarity of prescribing role; perceived lack of skills and 
knowledge; space and technology constraints; insufficient remuneration; and potential lack of 
managerial support (Giberson et al. 2011). 
2.6.1 Workload and time commitment:  
In a 2005 survey, both primary and secondary care pharmacists in England rated time 
commitment and workload as major obstacles that affect pharmacists to expand their 
professional role particularly in community pharmacy setting (George et al. 2006). In a UK 
study, Weeks et al. (2010) identified time management and work pressure as a barrier that 
hinders the ability of a pharmacist to prescribe. Makowsky et al. (2013) also reported prescribing 
as an additional workload in pharmacist’s work due to additional paperwork required.  
2.6.2 Clarity of prescribing role: 
A Canadian study evaluating how prescribing has changed the pharmacists’ role in 
primary care found that some pharmacists believed that they had acquired importance from the 
act of prescribing, particularly with physicians (Guirguis, et al. 2011). However, physicians 
appeared to maintain medical domination through their part in managing supplementary 
prescribing activities. In addition, the authors defined some situations in which pharmacists were 
doubtful about the definition of prescribing, such as recommending over-the-counter 
medications, continuing existing medications and making dose adjustments (Guirguis, et al. 
2011). 
2.6.3 Perceived lack of skills and knowledge: 
Many pharmacists are uncomfortable in performing diagnosis, have concerns about 
inadequate clinical examination skills, or are concerned they lack in-depth knowledge of patient 
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medical histories (Stewart et al. 2009; Tonna et al. 2007).  Furthermore, this concern about 
pharmacist competence also exists among other health professionals, most notably physicians.  
In a study by Hatah et al (2012), general practitioners (GP) expressed the concern that 
pharmacists do not know the patient well enough to prescribe appropriately, and this might result 
in inappropriate prescribing or cause a delay in appropriate medical advice or treatment and 
could be harmful to their patients. 
In the same study (Hatah et al. 2012), GP’s perceived that screening, monitoring, and 
pharmacist prescribing, particularly for repeat prescriptions and collaborative prescribing for a 
particular drug, contribute to discontinuous or fragmented patient-care. They were concerned 
that pharmacist-based services associated with prescribing might reduce the frequency of GPs 
seeing their patients, and perhaps impair the GP-patient relationship. They also thought these 
new services might reduce GP’s opportunities to talk with their patients about other health 
concerns and also decreased their overall picture of a patient’s health condition. 
Physicians were also less enthusiastic about pharmacist independent prescribing as they 
felt that medical training had taught them to manage uncertainty and take responsibility for 
making decisions based on clinical experience. They indicated that pharmacists, while worthy at 
following procedures, did not have the training or experience to make these independent 
decisions which are normally based on unclear reasons (Lloyd, Pearson, & Hughes, 2010). 
2.6.4 Access to consulting space/patient information: 
 Assessing patients may require a level of privacy and accessing patient information not 
routinely part of day-to-day pharmacy practice (Hatah et al. 2012 ; Lloyd et al., 2010), and the 
typical pharmacy counter does not provide a safe or appropriate space for discussing the 
management of medications (Gibson, 2008).  The lack of space/facilities can also prevent 
pharmacists with supplementary prescribing qualifications from concentrating on supplementary 
prescribing services rather than regular pharmacist responsibilities (George et al, 2006). 
According to one study (Hatah et al. 2012), in which it was proposed that pharmacists 
work within a medical practice, many GPs were concerned that they did not have enough space 
and computers available for pharmacists to provide their services. Some also bothered about 
pharmacists providing screening, monitoring, and prescribing since a pharmacy may not have a 
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private consulting room, so may not be an appropriate place for conducting physical 
examinations or to collect sensitive medical histories.  
An inadequate IT infrastructure was also identified among several stakeholders (clinical 
lead) in the United Kingdom and this involved practical issue such as not being able to print 
prescriptions and more general problems such as a lack of access to patients’ medical records 
(Cooper et al. 2008). Pharmacists also indicate difficulty in accessing medical records and 
sharing information (Lloyd, Pearson, & Hughes, 2010). 
2.6.5 Level of Remuneration: 
If remuneration is insufficient it may serve as disincentive to pharmacists (George et al. 
2006). In a study by Hatah et al, (2012) many GPs agreed that it would be ideal for pharmacists 
to provide Clinical Medication Review at the GPs’ practice; but some were concerned about who 
was going to pay for this service. Lack of payment is an issue that prevents pharmacists 
prescribing because to supervise a supplementary prescribing trainee in the UK, a general 
practitioner may expect to receive payment for it (Hobson & Sewell, 2006).   
2.6.6  Managerial support: 
Prescriptive authority and related cognitive activities may not be supported by an 
organization’s leadership. In England, a lack of support, trust and a reluctance to implement 
nonmedical prescribing were barriers to implementation in secondary care, as it was not 
considered to be a key priority (Lloyd, Pearson, & Hughes, 2010).  
Some other issues related to organization priorities included insufficient access to 
electronic health records, difficulties in identification of suitable patients due to lack of formal 
referral systems in place, and inadequate administrative support for the day-to-day running of the 
clinics; these issues are some of the potential reasons preventing pharmacists from moving 
forward toward getting independent prescribing authorities (George et al. 2006).   
2.7 Prescriptive Authority - Implications for Relationships 
Expanding scope of practice (e.g. prescriptive authority and minor illness prescribing) 
has the potential to demonstrate the value of the pharmacist to both physicians and patients. 
However, relations with prescribers may be adversely affected if viewed as encroachment or if 
recommendations are seen as inappropriate (Lloyd et al., 2010).  
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In studies by Lloyd, Pearson, & Hughes (2010) and Lloyd & Hughes (2007), some 
pharmacists felt there was reluctance among other health care providers, such as physicians and 
nurses, to share involvement in prescribing and a feeling of encroachment onto their territory. 
They also found some pharmacists think that it might be a bit awkward, working alongside with 
health care providers who also may be trying to become supplementary prescribers and feel that 
you are moving into their territory (Lloyd & Hughes, 2007).   
Some conflicts and professional tensions between non-physician prescribers (such as 
pharmacists and nurses) in the practice settings have also been observed where pharmacists have 
encroached upon nurses (Cooper et al. 2008).  
Although patients are expected to benefit from an expansion of scope of pharmacy 
practice, they may be concerned about new unfamiliar roles. Patients are getting quicker access 
to medication and average waiting time for patients by the physicians is also reduced (Stewart et 
al. 2009). Because pharmacists have better knowledge of drugs, patients can get a more detailed 
look at all their medications and can discuss the adverse effect of drugs in more detail with the 
pharmacist (Stewart et al. 2009).  
Improvement in patient care has been observed in terms of safety (safety checking around 
prescribing has become better and is continuing to become better), quality and continuity of care 
(Lloyd at al. 2010).  
2.8 Summary 
A review of the literature indicates that pharmacists have the experience in drug therapy 
management and have enough knowledge about prescription medicines to effectively manage the 
pharmaceutical care of their patients. Their roles and responsibilities within the health care 
system have been continuously changing since the early nineteen nineties. Previously 
pharmacists were viewed as a drug manufacturers and their role was limited to compounding, 
dispensing and labeling of drug products. Pharmacists evolved toward a more patient-oriented 
practice and developed the concept of clinical pharmacy.  
After getting involved in patient-oriented practice for decades, pharmacists became more 
experienced in patient care and health care delivery and made themselves an important part of 
the health care system.  
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In recent times some changes in the health care system have been made by introducing 
non-medical prescribing. The aim of introducing non-medical prescribing was to reduce general 
practitioners workload, improve patient access to medication, maintain continuity of patient care, 
and optimize medication management (Cooper et al. 2008; Nissen, L., 2011). In non-medical 
prescribing, limited prescriptive authority has expanded to other health care professionals, and 
pharmacists are one of them because they are highly trained health care professionals in 
medication management. More recently, pharmacists have begun to prescribe independently in 
some countries including parts of the United Kingdom, United States and Canada, but their 
authority of prescribing medicine is still limited. 
There are many reasons to justify new prescriptive authority for pharmacists such as 
increased patient access to medication, improvement in professional relationship with physicians, 
and better use of health care resources.  However, there are challenges that impede the 
effectiveness and widespread use of prescriptive authority such as workload and time 
commitment, lack of funding, and perceived professional encroachment.   Pharmacists have 
shown the ability to prescribe but they have to overcome some issues related to their skills like 
inadequate clinical examination skills and become uncomfortable in doing diagnosis etc. to move 
forward toward independent prescribing.  
Pharmacists have an important role to play as part of the health care community and also 
in addressing and resolving issues like patient safety, optimal health outcomes, financial 
sustainability and changing scope of practice of health care professionals by expanding their 
scope of practice.  
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2.9 Research Questions 
 To what extent has expanded prescriptive authority been integrated into community 
practice? 
 How have the characteristics of the community practice setting affected participation by 
community pharmacists in services associated with expanded prescriptive authority? 
◦ What aspects of practice are seen to support the use of prescriptive authority? 
◦ What aspects of practice are seen to challenge to use of prescriptive authority? 
 To what extent has expanded prescriptive authority affected the primary professional 
relationships of community pharmacists? 
◦ How have relations with patients been affected by prescriptive authority? 
◦ How have relations with physicians been affected by prescriptive authority? 
2.10    Hypothesis 
 Ho1:  There is no relationship between various practice characteristics and the 
participation in Level One Prescribing in SK 
 Ho2: There is no relationship between various practice characteristics and the 
participation in Minor Ailment Prescribing in SK 
 Ho3:  There is no relationship between participation in Level One Prescribing and the 
quality of the pharmacist’s relationship with patients in SK 
 Ho4:  There is no relationship between participation in Minor Ailment Prescribing and 
the quality of the pharmacist’s relationship with patients in SK 
 Ho5:  There is no relationship between participation in Level One Prescribing and the 
quality of the pharmacist’s relationship with physicians in SK 
 Ho6:  There is no relationship between participation in Minor Ailment Prescribing and 
the quality of the pharmacist’s relationship with physicians in SK 
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3. METHODOLOGY  
3.1 Study design 
To investigate the research questions, a quantitative survey design was used.  One of the 
reasons for using quantitative survey design is to collect details about the current knowledge and 
experience of community pharmacists within Saskatchewan about the issues related to their work 
activities and relationships. A qualitative study, while identifying specific issues would not allow 
extrapolation to the general community pharmacy population. Using a quantitative survey design 
enabled comparisons between different groups and also provided estimates from respondents that 
can be related to the entire population with a degree of certainty (Sukamolson, S. et al. 2005). 
  The design also allowed the study to obtain, measure, and analyze data, and to study in 
detail the relationship between independent and dependent variables.  A quantitative study also 
permitted statistical assessment of the extent that specific attitudes are held and behaviors 
displayed by the study population (Sukamolson, S. et al. 2005). 
 Although a quantitative method was originally selected to collect and analyze data, 
subsequent to giving to the field a large number of qualitative comments were received from the 
respondents. It was therefor decided appropriate to include those comments along with the 
quantitative results to give strength to the overall results. Hence, a mixed method approach was 
required to more fully address the research questions. A decision was made to use a sequential 
mixed method approach to collect and analyze both quantitative and qualitative data. A mixed 
method approach was seen to help in generalizing in-depth knowledge and experience of 
participants’ perceptions (Eli, 2009). 
   A mixed methods study involves the collection or analysis of both quantitative and/or 
qualitative data in a single study in which the data are collected concurrently or sequentially, are 
given a priority, and involve the integration of the data at one or more stages in the research 
process (Creswell et al. 2002; Eli, 2009). 
 Johnson and Turner (2003) also suggest that one of the strengths of designing a mixed 
method study which is opposed to either of the two separate methods (quantitative or qualitative)  
is that it gives complementary strengths and non-overlapping weaknesses. 
Since the purpose of this study was descriptive; a cross-sectional study design was used. 
Although it restricts the ability to show causality, it allowed the confirmation of relationships, to 
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acquire an understanding of issues at a point of time and it is relatively economical in terms of 
resources and time to complete (Sukamolson, S. et al. 2005). 
3.2      Study population and sample  
All registered practicing community pharmacists in Saskatchewan were eligible to 
participate in the study.  According to the National Association of Pharmacy Regulatory 
Authorities (NAPRA, 2013), there were 1416 pharmacists practicing in many different 
professional settings in Saskatchewan representing around 4.3 percent of the 33,000 pharmacists 
practicing in Canada (CPhA, 2013).  Of the 1416 practicing in Saskatchewan, 998 (70.5%) were 
identified as community pharmacists based on primary practice location as reported by the 
Saskatchewan College of Pharmacists.  
The sample size was calculated using proprietary software (Roasoft, 2013).  Based on a 
population of 998 community pharmacists, a sample of 278 was needed to obtain a confidence 
level of 95 percent and a margin of error of +/- 5 percent.  A review of similar studies indicated 
an expected response rate of between 30 and 35 percent (Perepelkin & Dobson, 2010; Doucette 
et al, 2006; Kreling et al, 2006; Schommer et al, 2006).  In order to achieve a 30 percent 
response rate a sample of 926 community pharmacists was required.  Given the size of the 
required sample and the relative size of the entire population, the decision was made to include 
all 998 community pharmacists in Saskatchewan.  The Saskatchewan College of Pharmacists 
agreed to provide the practice mailing addresses of all community pharmacists in Saskatchewan.    
3.3 Measures 
This study sought to understand the extent to which: community pharmacists in 
Saskatchewan have incorporated approved prescriptive authority services into their practices; 
how this is associated with characteristics of the practice location; and whether expanded 
prescriptive authority has affected their relationships with physicians and patients.  The measures 
described below sought to address these objectives and reflect the layout of the questionnaire that 
was used to collect the data. 
Part A- Integration of prescriptive authority into community pharmacy:   
All licensed community pharmacists with Level-1 prescribing training are eligible to 
prescribe for Level-1 conditions and some Minor ailment conditions in Saskatchewan 
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(Saskatchewan College of Pharmacists, 2010). Items under this section address the extent to 
which community pharmacists are actually involved in and perform these activities (Hill & 
Ramaswamy-Krishnarajan, 2005; CPhA, Sept. 2008). As well some items in this section were 
used to address how confident community pharmacists are in providing Level-1 and Minor 
ailment prescribing (Law et al., 2012).    
Part B- How Expanded prescriptive authority affects community practice setting:               
Items in this section were used to address issues related to the characteristics of the 
community pharmacist’s practice location (Law et al., 2012). This section of the questionnaire 
sought to address two major questions; first, what aspects of the practice location support 
prescriptive authority services and second, what aspects of the practice location challenge the use 
of prescriptive authority services.  
Items in this section include: How consistently do pharmacists at the location provide 
prescriptive authority services (Level-1 and Minor Ailment Prescribing); how much support do 
they get from the manager or the owner of their pharmacy (Lloyd et al., 2010); and whether or 
not documentation associated with the Level-1 and Minor Ailment Prescribing services deters 
them in providing Prescriptive Authority Services (Cooper et al. 2008). This section also 
contains some items that allowed respondents to give their views on liability issues within their 
workplace, and whether these issues affected their decision to offer Prescriptive Authority 
Services to their patients. Pharmacists were also asked to indicate their level of agreement on the 
issue of demands of other professional duties taking priority over PA services they provide 
(George et al. 2006). 
Part C- How Expanded prescriptive authority affects the primary professional 
relationships of community pharmacists:  
This section was developed to understand community pharmacist’s views of their 
primary professional relationships (Pharmacist prescribing task force, information paper, May-
June 2010). Items under this section fall under two sub categories: pharmacist’s relations with 
patients (Stewart et al. 2009); and pharmacist’s relations with physicians (Lloyd et al., 2010; 
Lloyd & Hughes, 2007). The first category of items was used to address the following: How 
knowledgeable their patients are about what PA services allow pharmacists to do; do the patients 
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satisfied with the PA services pharmacist provide; and whether pharmacists get any appreciation 
from their patients for the PA services they provide for them.  
Second category items were used to address: How knowledgeable physicians are about 
what PA services allow pharmacists to do; satisfaction level of the physician over PA services 
pharmacists provide; whether or not physicians accepting pharmacists as a PA service provider; 
to what extent physicians rely on the pharmacists providing PA services to their patients; and do 
the physicians have greater respect for pharmacists professional contribution because 
pharmacists provide PA service to their patients. 
Part D- The pharmacist completing the questionnaire:  
The importance of items under this section was to gather information about the 
demographics of the participant pharmacists. This section identified specifically information 
about the gender, age, education, degree earned, current position and the type of pharmacy they 
work at. 
Part E- Additional Comments:  
The purpose of this section in the questionnaire was to give participants some open space 
to write their additional comments if they thought the comment are relevant to the topic of the 
questionnaire. This section allowed them to write about any issue that they felt is important to 
rise, but has not been mentioned in the questionnaire.  
Five point Likert scales were used to give participants a “Neutral” option to ensure that 
they did not feel they were being forced to agree or disagree on an issue that they do not want to, 
or did not have enough knowledge about it. It was also felt that respondents might become 
frustrated by not having a mid-point and that could reduce the accuracy of data collection. 
Providing a mid-point also has some cons associated with it such as: it gives respondents an 
“Out” that means mid-point can be an easy option to choose for the respondents when they are 
unsure and the second reason is respondents may be less discriminating, meaning not take the 
time to weigh the merit of each response category (Losby & Wetmore, 2012). 
According to a survey conducted by Infosurv (2006) with a forum of market researchers 
to understand their preference between 5-point and 6-point likert scale, 71% participant of 
researchers agreed that the neutral rating is needed when conducting survey research; Only 12% 
preferred 6-point and 17% were neutral on the issue (Gwinner, 2006). 
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Both 5-point and 7-point Likert scales are most accurate as compared to smaller or larger 
scales (Alwin & Krosnick, 1991) and studies provide no grounds for preferring one over other 
(Johns, 2010). However, the 5-point Likert scale was given preference over 7-point to use in this 
study because it strikes a compromise between the conflicting goals of offering enough choice 
and making things convenient for respondents (Johns, 2010).  
3.4 Data collection 
A modified version of the Dillman method was used to obtain responses from the 
population (Dillman, 2000). Participants received an introductory notification letter (Appendix 
A) one week before the first questionnaire was sent out, which indicated the purpose of the 
survey and the reasons why they were selected as participants (Table 3.1). One week after the 
introductory notification letter, the first mailing of questionnaire was sent to the participants 
along with a cover letter and a pre-stamped return envelope (Appendix B & C). After 14 days a 
reminder card was posted to the non-responded participants indicating the importance of their 
input in the study (Appendix D). Fourteen days after the reminder letter participants received a 
second questionnaire (Appendix E).  
Table 3.1: Data collection timeline 
Activity Duration Date 
Notification Start Feb 4, 2014 
First Questionnaire One week Feb 11, 2014 
Reminder Two weeks Feb 25, 2014 
Second Questionnaire Two weeks Mar 11, 2014 
Second Reminder Two weeks Mar 25, 2014 
Data Concluded One month April 25, 2014 
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Two weeks after the second questionnaire a second reminder card was posted to the non-
responded participants indicating the importance of their input in the study (Appendix F). One 
month later the collection of data study was closed (Dillman, 2000; Ivencova, 2002).   
A mail survey was used to prevent any potential that the researcher may directly 
influence the responses (West, 2011). Along with the mail survey an online web link of 
questionnaire was also created to give participants an alternative option to participate in the 
survey, and to help maximize the overall response rate (Dillman, 2000). 
3.5 Data analysis 
3.5.1   Quantitative Analysis 
 All collected data were statistically analyzed using the latest available version (20.0) of 
IBM SPSS software for Windows. Descriptive statistics were reported for the demographics of 
the study populations.  Since the study aim was to get the opinion of participant pharmacists, the 
analysis was based on the average of their responses. In order to find group averages and 
variations within the groups, mean and standard deviation were performed followed by the t-test 
and One-way ANOVA for comparative analysis, mean differences between groups and 
significance differences. Post-hoc analysis (Scheffe’s Test) was used to confirm significant 
differences identified with ANOVA. Pearson’s r correlation tests were performed in order to 
determine the strength of correlations between continuous and interval data. 
3.5.2 Qualitative Analysis 
Qualitative data analysis is an essential part of the two step sequential mixed methods 
approach. Creswell et al. (2003) found that the quantitative followed by a qualitative method are 
the two distinct phases of a sequential mixed methods design. In this mixed methods approach 
researchers collect and analyze qualitative data (comments) in the second phase after collecting 
and analyzing quantitative data in the first phase of the study. Collecting and analyzing 
qualitative data in the second phase helps to explain and elaborate quantitative data. The rational 
of qualitative data analysis is that it helps to refine and explain quantitative findings by exploring 
respondents’ opinions in more depth (Creswell et al. 2003; Ivankova et al. 2006). 
In this study, qualitative data was collected in the form of participants’ comments. The 
Comments were analyzed by breaking them down into themes followed by sub-themes which 
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occurred via coding process (Sarantakos, 1998). Categorizing comments into themes helped to 
organize, understand, and interpret respondent’s perspective regarding issues mentioned in the 
questionnaire. Most suitable comments from each category were used along with the quantitative 
data to explore respondent’s views in more depth to answer the research questions. 
3.6 Validity 
 The validity of a questionnaire describes the “extent to which a measure accurately 
represents the concept it claims to measure” (Punch, 1998; Roberts et al. 2006). There are four 
major types of validity: face validity, content validity, construct validity, and criterion validity 
(Smith, 2005; Hoti, 2010).  
  Face validity is generally assessed to make sure information constructed by responses is 
appropriate (Smith, 2005; Hoti, 2010). It can be achieved by piloting the questionnaire with a 
group of representative participants similar to the intended study participants before 
administering it to actual population (Hoti, 2010; Roberts et al. 2006).  
 Content validity is assessed to ensure the relevance of the content of the questionnaire to 
the study purpose (Smith, 2005; Hoti, 2010). It can be achieved by piloting the questionnaire 
group of representative participants similar to the intended study participants, before 
administering it to actual population (Roberts et al. 2006).  
 Criterion validity is assessed to determine correlation between questions and the variable 
(Smith, 2005; Hoti, 2010). It is a strong form of validity. It can be achieved by comparing the 
questionnaire with similar validated measures of similar perceptions of phenomenon (Roberts et 
al. 2006). 
 Construct validity is assessed to determine if questions accurately reflect their concept 
(Smith, 2005; Hoti, 2010). Factor analysis is a popular way to determine construct validity by 
representing a number of statistical procedures used to determine characteristic correlation 
(Roberts et al. 2006).   
 For this study, face and content validity were assessed. Experts within the College of 
Pharmacy & Nutrition, University of Saskatchewan, and experienced community pharmacists 
were asked to evaluate face and content validity of the instrument prior to taking it to the field. 
The pilot questionnaire was administered to a group of three community pharmacists working in 
three different pharmacy locations and two experienced professors to detect and fix any defect, 
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wording issues, and confusion. This process was repeated three times in order to ensure the 
validity of the questionnaire content. There were no major corrections required in the 
questionnaire, as only a few minor issues were remedied.  
3.7 Reliability 
Reliability is one of the essential factors needed to generate an effective questionnaire. It 
can be defined as the extent to which “questions lead to reproducible responses that are internally 
consistent” (Smith, 2005; Hoti, 2010). Generally, there are two types of reliability; internal (the 
extent to which a measure is consistent within itself) and external (the extent to which a measure 
is varies from one use to another) (Mcleod, 2007). Internal reliability can be assesses by split-
half method (by splitting tests in halves and comparing results) and external reliability can be 
assesses by one of the two following methods: test re-test (by administering same test to the 
participants twice and comparing results) or inter-rater (by observing same behaviour 
independently and comparing results) (Mcleod, 2007).  
For this study, internal reliability was assessed by comparing responses of the first 
mailing with those of the second mailing. External reliability was assessed using the test re-test 
reliability method. A comparison was made between responses received via paper-based (mail) 
questionnaires vs online questionnaires.  
3.8 Ethical consideration 
 Issues related to ethics were addressed prior to start the survey study. All questions and 
research protocols were submitted to the ethics board of the University of Saskatchewan for their 
approval. Questionnaires were administered once the study got approved by the University of 
Saskatchewan Behavioural Research Ethics Board (BEH# 11-133) (Appendix G). 
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4. RESULTS 
4.1 Response Rate 
 Questionnaires were sent out to 998 eligible community pharmacists provided by the 
Saskatchewan College of Pharmacists. After the first mailing of the questionnaire and the first 
reminder letter, 340 questionnaires were returned including 20 online (Table 4.1). Seven 
questionnaires were returned as undeliverable due to a change in the location of the pharmacist. 
This reduced the number of eligible participants to 991; for a response rate after the first round of 
mailing of 34.3% (340/991). 
Table 4.1: Total responses received   
RESPONSE RECEIVED 
 After 
First Mailing 
After 
Second Mailing 
Total Undelivered 
Paper Based 
Questionnaires 
320 130 450 7 
On-line 
Questionnaires 
20 31 51 14 
Total 340 161 501 21 
  
After the second round of mailings 161 additional completed questionnaires were 
received, including 130 paper based and 31 online. An additional 14 were returned as 
undeliverable, resulting in a final response rate to 51.3% (501/977).  
In assessing internal reliability, no differences were found between first and second 
mailing responses.  In assessing external reliability very few statistical differences were found 
between mailing and on-line. Those responding online indicated that they are slightly more 
confident (L1 = 1.28 online vs. L1= 1.50 mail-in; MA = 1.77 online vs. MA = 2.06 mail-in) in 
providing Prescriptive Authority services (Level 1 (t = 2.757, p < 0.05) and MA (t = 2.452, p < 
0.05). 
The Independent sample t-test also revealed statistically significant differences between 
groups based on their age (t = 2.681, p < 0.05) with respect to the method of response (either 
mail or online). Average age of respondents that responded via mail was around 41 years while 
respondents that decided to respond online were around 37 years.  
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4.2 Demographic characteristics  
Data were collected of the demographic characteristics of all respondents (Table 4.2) 
including gender, age, current position, and the type of pharmacy in which they worked 
primarily. The majority of the participants (341, 68.1%) were females. Five respondents did not 
indicate their gender.  
The average age of respondents was 41 years.  The minimum age of respondents was 
reported at 23 years and maximum 83 years. A total of 55 (11%) respondents did not report their 
age. 
                     Table 4.2  Respondents demographic characteristics 
Variable 
 
Total Responses 
n (%) 
Sex 
Female 
Male 
341 (68.1) 
155 (30.9) 
Total 496 (99) 
Age Years  
Maximum 
Minimum 
Mean 
83 
23 
40.9 
Current Position*  
Staff Pharmacist 
Manager 
Associate 
Owner 
Other 
305 (60.9) 
119 (23.8) 
8 (1.6) 
59 (11.8) 
7 (1.4) 
Total 498 (99.4) 
Pharmacy Type 
Independent 
Small Chain 
Banner 
Large Chain 
Franchise 
Grocery Store 
Department Store 
Mass Merchandiser 
Other 
115 (23.0) 
20 (4.0) 
77 (15.4)  
104 (20.8) 
52 (10.4) 
90 (18.0) 
7 (1.4) 
21 (4.2) 
9 (1.8) 
Total 495 (98.8) 
               *Merged Staff Pharmacists and Other into one category for analysis 
                  *Merged Associate and Owner into one category for analysis 
 
In identifying their primary practice locations, 42.4 percent (212) of respondents 
indicated that they worked either at an independent pharmacy, a banner or a small chain 
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pharmacy. More than thirty percent (157) indicated they worked in either a franchise or a large 
chain pharmacy. The remaining respondents (127, 25.1%) indicated the pharmacy type as 
grocery store, departmental store, mass merchandiser or other (consultancy clinic). Six 
participants (1.2 %) did not respond to the question. 
4.3 Descriptive Analysis of the Results 
4.3.1 Respondents participation in Prescriptive Authority Services 
Study participants were asked to indicate their confidence in providing Level 1 and 
Minor Ailment Prescribing to their patients (Table- 4.3). For this study, Level 1 prescribing 
included activities such as: emergency prescription refills, renew/extend prescriptions, changing 
drug dosage/formulation, and therapeutic substitution. Minor Ailments (MA) prescribing 
included all activities associated with initiating a prescription for a MA condition (i.e., acne, cold 
sores, insect bites, allergic rhinitis, oral ulcers, oral thrush, and diaper rash).   
Table 4.3: Respondents participation in Prescriptive Authority Services: 
 
Question 
Type of 
Prescribing 
Strongly 
Agree 
n 
(%) 
Agree 
 
n 
(%) 
Neutral 
 
n 
(%) 
Disagree 
 
n 
(%) 
Strongly 
Disagree 
n 
(%) 
Total 
Responses  
n  
(%) 
Mean 
SD 
P 
Value 
I am confident 
in my ability 
to provide 
Prescriptive 
Authority 
Services to 
my patients.  
Level 1 
285 
(56.9) 
186 
(37.1) 
14 
(2.8) 
4 
(0.8) 
3 
(0.6) 
492 
(98.2) 
-0.569 
 0.839 
<.001 
Minor 
Ailment 
110 
(22.0) 
268 
(53.5) 
75 
(15.0) 
22 
(4.4) 
3 
(0.6) 
478 
(95.4) 
 
The vast majority of respondents (94%) agreed or strongly agreed that they were 
confident in their ability to provide Level 1 prescribing to the patients. When they were asked the 
same question about Minor Ailment Prescribing more than 75 percent agreed or strongly agreed. 
Very few respondents indicated less confidence in their ability to provide either Level 1 or Minor 
Ailment Prescribing. 
The paired sample t-test was performed to determine whether there were significant 
differences between responses in relation to their confidence in the ability to provide 
Prescriptive Authority Services (Level 1 and MA Prescribing). The test revealed a statistically 
significant difference (p < 0.001) in their confidence to provide the two types of prescribing 
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services (Mean = -0.569, SD = 0.839).  The difference was also viewed significant (>0.5) with 
participants more confident in providing Level 1 services.  
In comparing the groups based on their sex, independent sample t-tests were performed to 
compare pharmacist’s confidence in providing Prescriptive Authority services. In the case of 
Level 1, there was no statistically significant difference between groups (t = 0.551, P > 0.05). As 
well no differences based on sex was seen for MA (t = 1.813, p >0.05). 
One-way ANOVA was conducted to determine the difference amongst groups based on 
the current job position of the pharmacists (Staff Pharmacist, Manager, and Owner/Associate). 
There were no statistical significant differences among groups in the case of Level 1(F (2, 486) = 
1.666, p > 0.05). In the case of MA prescribing there was a statistical significant difference (F (2, 
472) = 4.739, p < 0.05); however, post-hoc analysis for homogeneous subsets revealed no such 
differences (p > 0.05) among groups.  
One-way ANOVA revealed no statistical significant differences among groups based on 
their age ((3, 437) = 1.849, p > 0.05) in the case of Level 1 prescribing; however, statistical 
significant differences were observed in the case of MA prescribing (3, 423) = 3.719, p < 0.05) 
(Table 4.4).  
Table 4.4: One-way ANOVA (Showing significant differences based on Age) 
Question  Sum of Squares Df Mean Square F  Sig. 
I am confident in my 
ability to provide Minor 
Ailment Prescribing 
Services to my patients. 
Between Groups 
Within Groups 
Total 
6.802 
256.082 
262.884 
3 
420 
423 
2.267 
0.610 
3.719 0.012 
 
Post hoc analysis indicated statistical significant differences amongst groups based on 
age in the case of MA prescribing (Table 4.5). Respondents between the age of 23-30 indicated a 
higher confidence level (1.88/5) than the respondents between the age of 51-83 (2.21/5). 
Table 4.5: Post-hoc analysis based on Age 
Age quartiles N 
Subset of alpha = 0.05 
1 2 
23-30 
31-40 
41-50 
51-83 
Sig. 
106 
131 
90 
97 
1.88 
1.94 
2.09 
 
0.284 
 
1.94 
2.09 
2.21 
0.109 
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One-way ANOVA revealed no statistical significant differences among groups based on 
location of the pharmacy (community size): rural & small town (<1000 people), small city (1k- 
30k people), medium city (30k- 100k) and large city (>100k people) (Statistics Canada, 2011) 
((Level 1 (F (3, 487) = 0.434, p > 0.05), MA (F (3, 473) = 0.132, p > 0.05)). 
4.3.1.1 Respondents participation in Prescriptive Authority Services 
Participants were asked to respond to two questions about the percent of all opportunities 
in which they actually provided Level 1 and Minor Ailment Prescribing to patients (Table 4.6). 
For Level 1 Prescribing, respondents indicated on average that they provided this service to their 
patients about three-quarters (74.2%) of the time when the opportunity presented itself. In the 
case of Minor Ailment Prescribing, respondents indicated on average that they provided this 
service approximately half of the time (52.5%). 
Table 4.6: Respondents participation in Prescriptive Authority Services: 
 
Question 
Response quintile (%) Rate of 
Participation 
(%) 
Paired 
Difference P 
Value 
0-20 21-40 41-60 61-80 81-100 
Mean 
(SD) 
Of all the 
opportunities I 
have to provide 
Prescriptive 
Authority 
Services, the 
percent of 
which I actually 
provide these 
prescribing 
activities. 
Level 1 8.4 2.8 9.2 36.6 43.1 74.2 
21.697 
(26.890) 
 
<.001 
 
Minor 
Ailment 
25.8 9.2 20 29.6 15.6 52.5 
 
A majority of respondents (43%) reported on average that they provide Level 1 
prescribing services to their patients almost every time (90+%). However, around 37 percent 
indicated on average that they provide this service around three-quarters of the time; while a very 
few (20%) indicated on average that they provided this service less than half of the time (Table 
4.6) (Figure 1).  
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Figure 1: Respondents participation in Level 1 Prescribing Services 
  
 
Figure 2: Respondents participation in Minor Ailment prescribing services 
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Respondents reported a totally different view for the same question in the case of Minor 
Ailment prescribing, only a few respondents (15.6 %) indicated on average that they provided 
this service to the patients almost every time (90+%) when the opportunity presented to them. 
However, around 30 percent indicated on average that they provide this service almost three-
quarters of the time; while a majority of respondents (55%) indicated on average that they 
provide MA services less than half of the time to the eligible patients. (Table 4.6) (Figure 2). 
A statistically significant difference (p < 0.001) was observed among respondents in 
relation to the percent of all opportunities in which they actually provide these services to their 
patients (M = 21.697, SD = 26.890) (Table 4.6).  
The Independent sample t-test revealed statistically significant differences between 
groups based on their sex for Level 1 (t = 1.983, p < 0.05) and MA (t = 2.116, p < 0.05) 
prescribing. Female respondents were more likely to agree that they actually provide these 
services more often (L1 = 75.9, MA = 54.9) than males (L1 = 71.3, MA = 48.2). 
In order to increase validity of the data a non-parametric analysis was performed with the 
assumption that normal distribution is not met. The Wilcoxon Signed Ranks test revealed 
statistically significant differences (z = -14.93, p < 0.001) between: of all the opportunities I have 
to provide Level 1 prescribing, the percent of which I actually provide and of all the 
opportunities I have to provide MA prescribing, percent of which I actually provide. The results 
indicate that the respondents actually provide MA prescribing slightly more often than Level 1. 
One-way ANOVA based on Age revealed statistically significant differences among 
groups in both the cases (Table 4.7). Post hoc analysis confirmed that there were statistical 
significant differences among groups based on age. However, in the case of Level 1 prescribing 
the differences were marginally significant (Table 4.8) but, in the case of MA prescribing 
differences were strongly significant (Table 4.9). 
Table 4.7: One-way ANOVA (Showing significant differences based on Age) 
Question  Sum of Squares Df Mean Square F  Sig. 
Of all the opportunities I have to 
provide Level 1 prescribing, the 
percent of which I actually 
provide Level 1 prescribing 
activities. 
Between Groups 
Within Groups 
Total 
10411.691 
243480.910 
253892.601 
3 
442 
445 
3470.56 
550.862 
6.300 0.000 
Of all the opportunities I have to 
provide Minor Ailment 
prescribing, the percent of which 
I actually provide Minor Ailment 
prescribing activities. 
Between Groups 
Within Groups 
Total 
36826.326 
403859.772 
440686.099 
3 
442 
445 
12275.4 
913.710 
13.40 0.000 
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Table 4.8: Post-hoc analysis based on Age (Level 1) 
Age quartiles 
N 
Subset of alpha = 0.05 
1 2 
51-83 
41-50 
23-30 
31-40 
Sig. 
103 
94 
111 
138 
67.28 
72.13 
 
 
0.508 
 
72.13 
77.48 
79.57 
0.141 
Table 4.9: Post-hoc analysis based on Age (MA) 
Age quartiles N 
Subset of alpha = 0.05 
1 2 3 
51-83 
41-50 
31-40 
23-30 
Sig. 
103 
94 
138 
111 
39.51 
46.70 
 
 
0.379 
 
46.70 
57.83 
 
0.062 
 
 
57.83 
63.06 
0.651 
 
In the case of Level 1 prescribing, respondents between the ages of 31-40 indicated that 
they provide this service to the patients slightly more often than the respondent between the ages 
of 51-83 (Table 4.8). However, in the case of MA prescribing respondents between the ages of 
23-30 indicated that they provide this service much more often than the respondents between the 
ages of 51-83 (Table 4.9). 
Non-parametric version of ANOVA was also performed in the form of Kruskal Wallis 
test. The test revealed no statistical significant difference (p > 0.05) among groups based on age 
in both the cases. Post hoc analysis confirmed that there were no statistical significant 
differences among groups based on age. 
One-way ANOVA based on job position revealed no statistical significant differences 
among groups for Level 1. In the case of MA, there was a statistical significant difference (Table 
4.10). Post-hoc analysis indicated that there were some differences amongst the opinions of 
Owner or Associate and Manager in relation to the percent of which they actually provide MA 
services (Table 4.11). 
Table 4.10: One-way ANOVA (Showing significant differences based on job position) 
Question  Sum of Squares Df Mean Square F  Sig. 
Of all the opportunities I 
have to provide Minor 
Ailment prescribing, the 
percent of which I actually 
provide Minor Ailment 
prescribing activities. 
Between Groups 
Within Groups 
Total 
6328.001 
483326.015 
489654.016 
2 
495 
497 
3164.001 
976.416 
3.240 0.040 
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Table 4.11: Post-hoc analysis based on job position 
Position N 
Subset of alpha = 0.05 
1 2 
Owner/Associate 
Staff Pharmacist 
Manager 
Sig. 
67 
312 
119 
47.61 
51.44 
 
0.654 
 
51.44 
58.57 
0.231 
 
Pharmacy managers indicated that they actually provide this service more often (58.6%) 
than Owners or Associates (47.6%) when the opportunity presented to them. 
Non-parametric version of ANOVA was also performed in the form of Kruskal Wallis 
test. The test revealed no statistical significant difference (p > 0.05) among groups based on job 
position in both the cases. Post hoc analysis confirmed that there were no statistical significant 
differences among groups based on job position. 
One-way ANOVA revealed no statistical significant differences among groups based on 
the location of the pharmacy. 
A Pearson’s r data analysis revealed moderately strong correlation (0.3 to 0.5) (Cohen, 
1988) between pharmacist’s confidences in providing Prescriptive Authority services and the 
percent of which they actually provide these services (Table 4.12).  
Although the overall correlation is moderately strong, the pharmacist’s confidence in 
providing MA prescribing services correlate more strongly with the percent of time they actually 
provide the services (Table 4.12). 
Table 4.12: Correlations (Pearson’s r data analysis) 
 Of all the opportunities I have to 
provide Level 1 Prescribing, the 
percent of which I actually 
provide these prescribing activity 
Of all the opportunities I have to 
provide Minor Ailment 
Prescribing, the percent of which I 
actually provide these prescribing 
activity 
I am confident in my ability to 
provide Level 1 Prescribing Services 
to my patients. 
-0.353 
0.000 
492 
-0.224 
0.000 
492 
I am confident in my ability to 
provide Minor Ailment prescribing 
Services to my patients. 
-0.184 
0.000 
478 
-0.500 
0.000 
478 
 
Participants were also asked to estimate the amount of time they take to provide Minor 
Ailment Prescribing to their patients (Table 4.13). 
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Table 4.13: Respondents participation in Prescriptive Authority Services: 
 
Question 
Response (min) 
Minimum 
(minutes) 
Maximum 
(minutes) 
Mean 
(minutes) 
 
Total 
Respons
es 
N 
0-5 5-10 10-15 15-20 20-30 30-60 
On average, in 
terms of 
minutes, how 
much time 
does it take 
you to provide 
Minor 
Ailment 
prescribing 
services to a 
patient for one 
of the seven 
listed 
conditions? 
2.4  20.8  34.8 23.4   8.2 0.6 4 60 16.1 452 
 
Respondents indicated that the average time they used to provide minor ailment 
prescribing was 16.1 minutes. A vast majority of respondents (81.4 %) indicated that on average 
it took twenty minutes or less to provide this service to their patients while less than 10 percent 
(8.8 %) indicated that it took more than twenty minutes. Approximately ten percent of 
participants did not respond to the question. 
The Independent sample t-test revealed statistical significant differences between male 
and female pharmacists (t = 2.377, p < 0.05) in relation to the average time they provide MA 
Prescribing services. Mean difference indicate that female pharmacists (16.5 min.) took slightly 
more time than males (15 min.). 
One-way ANOVA based on Age revealed statistical significant differences among groups 
(Table 4.14). Post-hoc analysis indicated that there were some differences amongst the opinions 
of respondents based on their age (Table 4.15).   
Table 4.14: One-way ANOVA (Showing significant differences based on Age) 
Question  Sum of Squares Df Mean Square F  Sig. 
On average, in terms of 
minutes, how much time 
does it take you to provide 
Minor Ailment 
prescribing services to a 
patients 
Between Groups 
Within Groups 
Total 
315.996 
14606.717 
14922.712 
3 
401 
404 
105.332 
36.426 
2.892 0.035 
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Table 4.15: Post-hoc analysis based on Age 
Age quartiles N 
Subset of alpha = 0.05 
1 2 
23-30 
31-40 
51-83 
41-50 
Sig. 
107 
126 
84 
88 
14.95 
15.65 
16.12 
 
0.508 
 
15.65 
16.12 
17.44 
0.229 
 
Respondents between the age of 41-50 indicated that on an average they take slightly 
more time to provide MA prescribing (17.44 min) than the respondents between the age of 23-30 
(14.95 min) (Table 4.15). 
Analysis using One-way ANOVA revealed no statistical significant differences among 
groups based on sex (Female and Male pharmacists) and location of pharmacy (Rural and Small 
Town, Large City, Small City and Medium City). 
4.3.2 Respondent’s level of concern about professional liability associated with Level 1 and 
Minor Ailment prescribing:   
A large percent of respondents (354, 70.7%) disagreed or strongly disagree with being 
concerned with the issue of professional liability with Level 1 prescribing (Table 4.16); 61.1 
percent (306) of respondents indicated the same for minor ailment prescribing. 
Table 4.16: Professional liability concerns associated with Level 1 and Minor Ailment 
Prescribing: 
 
Question 
Type of 
Prescribing 
Strongly 
Agree 
n 
(%) 
Agree 
 
n 
(%) 
Neutral 
 
n 
(%) 
Disagree 
 
n 
(%) 
Strongly 
Disagree 
n 
(%) 
Total 
Responses  
n  
(%) 
Mean 
SD 
P 
Value 
Concerns about 
liability affect 
my decision to 
offer some 
Prescriptive 
Authority 
Services 
Level 1 
10 
(2.0) 
61 
(12.2) 
72 
(14.4) 
251 
(50.1) 
103 
(20.6) 
497 
(99.2) 
0.178 
0.759 
<.001 
Minor 
Ailment 
10 
(2.0) 
81 
(16.2) 
80 
(16.0) 
235 
(46.9) 
71 
(14.2) 
477 
(95.2) 
  
While most respondents were generally not concerned about professional liability, 
approximately 14 percent (71) (Level1) and 18 percent (91) (MA) agreed or strongly agreed that 
they had concerns.  
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 A statistically significant difference (p < 0.001) was found between respondent’s 
opinions regarding their concerns about liability with respect to two type of prescribing (M = 
0.178, SD = 0.759) (Table 4.16). 
Analysis using One-way ANOVA revealed no statistical significant differences among 
groups based on the location of the pharmacy. 
4.3.3 Respondents concerns about the characteristics of the community practice setting 
affected participation by community pharmacists in services associated with expanded 
prescriptive authority 
When asked whether their pharmacy consistently provide Level 1 Prescribing services to 
the patients (Table 4.17), 90 percent (451/493) strongly agreed or agreed to the statement. In the 
case of Minor Ailment Prescribing almost 53 percent (265/481) respondents strongly agreed or 
agreed. 
When asked about whether the pharmacy manager supports Level 1 prescribing in their 
pharmacy, approximately 96 percent (479/493) of respondents strongly agreed or agreed to the 
statement. In the case of Minor Ailment Prescribing 88 % (441/485) strongly agreed or agreed. 
A mixed response was observed when participants were asked whether paperwork 
associated with prescriptive authority services (Level 1 and MA Prescribing) deters them 
offering these services. More than two-thirds of respondents (339/494, 67.6 %) strongly 
disagreed or disagreed to the statement for Level 1Prescribng. In the case of MA Prescribing 
only 44 percent (219/480) strongly agreed or agreed. 
Respondents were also asked whether the demands of their other professional duties 
sometimes took priority over Prescriptive Authority Services. Almost 55 percent (271/494) 
respondents strongly disagreed or disagreed while 25.4 percent (127/494) strongly agreed or 
agreed in the case of Level 1 Prescribing. For MA Prescribing almost 50 percent (249/486) 
respondents strongly agreed or agreed and 28.2 percent (141/486) strongly disagreed or 
disagreed. 
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Table 4.17: Respondents confident about their ability to provide prescriptive authority 
services (Level 1 and Minor ailment prescribing) to the patients 
 
 
Question 
Type of 
prescribing 
Strongly 
Agree 
n 
(%) 
Agree 
 
n 
(%) 
Neutral 
 
n 
(%) 
Disagree 
 
n 
(%) 
Strongly 
Disagree 
n 
(%) 
Total 
Responses  
n  
(%) 
Mean 
SD 
P 
Value 
My pharmacy 
consistently 
provides 
Prescriptive 
Authority 
services to our 
patients.  
Level 1 
246 
(49.1) 
205 
(40.9) 
22 
(4.4) 
15 
(3.0) 
5 
(1.0) 
493 
(98.4) 
-0.989 
 1.106 
<.001 
Minor 
Ailment 
60 
(12.0) 
205 
(40.9) 
99 
(19.8) 
89 
(17.8) 
28 
(5.6) 
481 
(96.0) 
The pharmacy 
manager 
supports 
Prescriptive 
Authority 
services in this 
pharmacy.  
Level 1 
353 
(70.5) 
126 
(25.1) 
9 
(1.8) 
3 
(0.6) 
2 
(0.4) 
493 
(98.4) 
-0.287 
 0.570 
<.001 
Minor 
Ailment 
250 
(49.9) 
191 
(38.1) 
35 
(7.0) 
5 
(1.0) 
4 
(0.8) 
485 
(96.8) 
Paperwork 
associated with 
Prescriptive 
Authority 
services often 
deters me from 
offering these 
services. 
Level 1 
17 
(3.4) 
70 
(14.0) 
68 
(13.6) 
208 
(41.5) 
131 
(26.1) 
494 
(98.6) 
0.891 
1.171 
<.001 
Minor 
Ailment 
55 
(11.0) 
164 
(32.7) 
97 
(19.4) 
124 
(24.8) 
40 
(8.0) 
480 
(95.8) 
The demands of 
my other 
professional 
duties take 
priority over 
Prescriptive 
Authority 
services. 
Level 1 
25 
(5.0) 
102 
(20.4) 
96 
(19.2) 
198 
(39.5) 
73 
(14.6) 
494 
(98.6) 
0.707 
1.053 
<.001 
Minor 
Ailment 
72 
(14.4) 
177 
(35.3) 
96 
(19.2) 
116 
(23.2) 
25 
(5.0) 
486 
(97.0) 
 
As displayed in table 4.17, there were statistically significance differences (p < 0.001) 
among respondent’s opinions. Substantial difference (>0.5) were seen for three of the four items 
including; pharmacy consistently providing these services, effect of associated paperwork and 
the demands of other professional duties. 
The independent sample t-test revealed no statistical significant differences between 
groups (first versus second mailing) in the case of MA Prescribing. For Level 1, there were 
statistical significant differences in two of the four items including the question pharmacy 
consistently providing Level 1 services (t = -2.457, p < 0.05) and pharmacy manager supports 
Level 1 prescribing (t = -2.588, p < 0.05). The number of respondents responded to the first 
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mailing indicating their pharmacies are slightly more consistent in providing Level 1 prescribing 
(M = 1.82) than the respondents who responded to the second mailing (M = 1.59). In the case of 
Managers’ support, the respondents’ that responded to the first mailing indicated slightly more 
support (M = 1.29) than the respondents who responded to the second mailing (M = 1.47). 
Paired sample t-test revealed no statistical significant differences between groups (Male 
and Female Pharmacists) in the case of MA Prescribing (Table 4.18). For Level 1 there were 
statistical significant differences in one of the four items including the demands of other 
professional duties take priority over Level 1 Prescribing. The number of females disagreed or 
strongly disagreed with the statement “professional duties take priority over Level 1” was more 
than the males (Table 4.18).  
Table 4.18: Paired sample T-Test 
Question Type 
Paired Difference 
T Df 
Sig.  
(2-tailed) Mean Std. D 
I am confident in my ability to 
provide Prescriptive Authority 
Services to my patients. 
      Level 1 
-0.57 0.84 -14.80 475 <.001 Minor 
Ailment 
Of all the opportunities I have to 
provide Prescriptive Authority 
Services, the percent of which I 
actually provide these prescribing 
activity (please circle most 
appropriate percent). 
Level 1 
21.7 26.89 18.06 500 <.001 
Minor 
Ailment 
Concerns about liability affect my 
decision to offer some Prescriptive 
Authority Services 
Level 1 
0.18 0.76 5.13 475 <.001 Minor 
Ailment 
My pharmacy consistently provides 
Prescriptive Authority services to our 
patients. 
Level 1 
-0.99 1.11 -19.58 478 <.001 Minor 
Ailment 
The pharmacy manager supports 
Prescriptive Authority services in this 
pharmacy. 
Level 1 
-0.29 0.57 -11.08 483 <.001 Minor 
Ailment 
Paperwork associated with 
Prescriptive Authority services often 
deters me from offering these 
services.  
Level 1 
0.89 1.17 16.65 478 <.001 Minor 
Ailment 
The demands of my other 
professional duties take priority over 
Prescriptive Authority services. 
Level 1 
0.71 1.05 14.79 484 <.001 Minor 
Ailment 
 
One-way ANOVA revealed statistically significant differences among groups in two of 
the four items in both cases (Level 1 and MA) based on the job position (Table 4.19). Item 
includes: Pharmacy manager support for Prescriptive Authority and the demands of other duties 
take priority over PA. 
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Table 4.19: One-way ANOVA (Showing significant differences based on job position) 
Question  Sum of Squares Df Mean Square F Sig. 
The pharmacy manager 
supports Level 1 
prescribing in this 
pharmacy. 
Between Groups 
Within Groups 
Total 
2.891 
164.515 
167.406 
2 
487 
489 
1.446 
0.338 
4.279 0.014 
The demands of my other 
professional duties take 
priority over Level 1 
prescribing.  
Between Groups 
Within Groups 
Total 
10.684 
600.237 
610.921 
2 
488 
490 
5.342 
1.230 
4.343 0.014 
The demands of my other 
professional duties take 
priority over MA 
prescribing. 
Between Groups 
Within Groups 
Total 
12.011 
618.523 
630.534 
2 
480 
482 
6.005 
1.289 
4.660 0.010 
 
There were statistically significant differences among groups in the case of Level 1 for 
the first item. Staff Pharmacists and Owners/Associates both agreed to the fact that managers’ 
support Level 1 prescribing in their pharmacy. However, the mean score of Staff Pharmacists 
(1.38) was slightly higher than Owners/Associates (1.17) (Table 4.19). In the case of MA, Post-
hoc analysis revealed no differences between groups.  
In relation to the second item, statistically significant differences were observed among 
the groups for both forms of Prescribing Level 1 and MA (Table 4.19). Pharmacy Managers 
were more likely to disagree (3.63) with the fact that other professional duties take priority over 
Level 1 but, Owners/Associates were more inclined towards a Neutral option (3.18). In the case 
of MA, Managers were almost Neutral (2.96) to the statement but, most of the 
Owners/Associates were more likely to agree (2.52) to the fact that other professional duties take 
priority over MA Prescribing. 
Table 4.20: One-way ANOVA (Showing significant differences based on location) 
Question  Sum of Squares df Mean Square F Sig. 
The pharmacy manager 
supports Level 1 
prescribing in this 
pharmacy. 
Between Groups 
Within Groups 
Total 
3.054 
165.261 
168.315 
2 
488 
491 
1.018 
0.339 
3.006 0.030 
 
Based on the location of the pharmacy, One-way ANOVA revealed statistically 
significant differences among groups in one of the four items only in the case of Level1 
prescribing (Table 4.20); Item: Pharmacy manager support for Level 1 prescribing by 
pharmacists. Post-hoc analysis later confirmed the differences among groups; both groups of 
pharmacists working in the large cities and the medium cities agreed to the fact that managers’ 
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support Level 1 Prescribing in their pharmacy. However, the mean score of the pharmacists 
working in medium cities (1.55) was a bit higher than the one working in the large cities (1.28). 
A Pearson’s r data analysis revealed moderately strong correlation between variables 
(Table 4.21).  
All four of the questions that respondents were asked about their engagement in 
Prescriptive Authority services have shown moderately strong correlation with the percent of 
which they actually provide these services. However, overall correlation in the case of MA 
prescribing is found to be slightly stronger than Level 1(Table 4.21). 
Table 4.21: Correlations (Pearson’s r data analysis) 
 Of all the opportunities I 
have to provide Level 1 
Prescribing, the percent 
of which I actually 
provide these 
prescribing activity 
Of all the opportunities I 
have to provide Minor 
Ailment Prescribing, the 
percent of which I 
actually provide these 
prescribing activity 
My pharmacy consistently 
provides Prescriptive 
Authority services to our 
patients. 
Level 1 
-0.375 
0.000 
493 
-0.172 
0.000 
493 
Minor 
Ailment 
0.274 
0.000 
481 
-0.567 
0.000 
481 
The pharmacy manager 
supports Prescriptive 
Authority services in this 
pharmacy. 
Level 1 
-0.317 
0.000 
493 
-0.242 
0.000 
493 
Minor 
Ailment 
-0.226 
0.000 
485 
-0.414 
0.000 
485 
Paperwork associated with 
Prescriptive Authority 
services often deters me 
from offering these 
services. 
Level 1 
0.330 
0.000 
494 
0.173 
0.000 
494 
Minor 
Ailment 
0.154 
0.001 
480 
0.453 
0.000 
480 
The demands of my other 
professional duties take 
priority over Prescriptive 
Authority services. 
Level 1 
0.306 
0.000 
494 
0.251 
0.000 
494 
Minor 
Ailment 
0.240 
0.000 
486 
0.484 
0.000 
486 
 
Two of the four questions about their engagement in Prescriptive Authority services 
correlated positively with the percent of which they actually provide these services and the other 
two correlated negatively. The one that correlated negatively was: The pharmacy consistently 
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provides PA Services and Pharmacy managers’ support. The one that correlated positively was: 
Paperwork associated with PA Services and the demands of other professional duties take 
priority (Table 4.21). 
4.3.4 Participant’s perception of patient’s attitude toward Prescriptive Authority Services 
(Level 1 and Minor Ailment) 
Participants were asked three questions about patient attitudes for both Level 1 and MA 
prescribing. Almost 40 percent (199/497) respondents indicated that their patients seemed 
knowledgeable about what Level 1 Prescribing allowed pharmacists to do for them. Almost 36 
percent (181/497) strongly disagreed or disagreed with the statement and 23.4 percent (117/497) 
were neutral.  
Table 4.22: Participant’s perception of patient’s attitude toward prescriptive authority 
services (Level 1 and Minor Ailment) 
 
 
Question 
Type of 
prescribing 
Strongly 
Agree 
n 
(%) 
Agree 
 
n 
(%) 
Neutral 
 
n 
(%) 
Disagree 
 
n 
(%) 
Strongly 
Disagree 
n 
(%) 
Total 
Responses  
n  
(%) 
Mean 
SD 
P 
Value 
My patients 
seem 
knowledgeabl
e about what 
Prescriptive 
Authority 
Services 
allows me to 
do for them. 
Level 1 
20 
(4.0) 
179 
(35.7) 
117 
(23.4) 
149 
(29.7) 
32 
(6.4) 
497 
(99.2) 
-0.574 
 1.001 
<.001 
Minor 
Ailment 
8 
(1.6) 
62 
(12.4) 
119 
(23.8) 
225 
(44.9) 
65 
(13.0) 
479 
(95.6) 
My patients 
appear to be 
satisfied with 
the 
Prescriptive 
Authority 
Services I 
provide. 
Level 1 
155 
(30.9) 
310 
(61.9) 
25 
(5.0) 
3 
(0.6) 
0 
(0.0) 
493 
(99.2) 
-0.177 
 0.651 
<.001 
Minor 
Ailment 
123 
(24.6) 
263 
(52.5) 
69 
(13.8) 
9 
(1.8) 
0 
(0.0) 
464 
(92.6) 
My patients 
seem to have a 
greater 
appreciation 
for my 
abilities 
because of 
Prescriptive 
Authority 
Service 
Level 1 
79 
(15.8) 
211 
(42.1) 
147 
(29.3) 
50 
(10.0) 
6 
(1.2) 
493 
(98.4) 
0.280 
0.799 
<.001 
Minor 
Ailment 
110 
(22.0) 
221 
(44.1) 
110 
(22.0) 
20 
(4.0) 
2 
(0.4) 
463 
(92.4) 
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Almost 63 percent (290/479) of respondents strongly disagreed or disagreed to the same 
statement about MA prescribing with 23.8 percent (119/479) neutral (Table 4.22).  
A vast majority of respondents (465/493, almost 93%) strongly agreed or agreed when 
they were asked whether their patients appear to be satisfied with the Level 1 Prescribing 
services they provided for them. In the case of MA Prescribing 77.1 percent (386/464) 
respondents strongly agreed or agreed.  
The last question in this section asked whether patients seemed to have a greater 
appreciation for pharmacists’ abilities because of Level 1 Prescribing. Almost 58 percent 
(290/493) respondents strongly agreed or agreed to the statement. In the case of MA Prescribing 
66.1 percent (331/463) respondents strongly agreed or agreed.  
Table 4.23: Paired sample T-Test 
Question Type 
Paired Difference 
t Df 
Sig.  
(2-tailed) Mean Std. D 
My patients seem knowledgeable 
about what Prescriptive Authority 
Services allows me to do for 
them. 
      Level 1 
-0.57 1.00 -12.54 476 <.001 Minor 
Ailment 
My patients appear to be satisfied 
with the Prescriptive Authority 
Services I provide. 
Level 1 
-0.18 0.65 -5.86 461 <.001 Minor 
Ailment 
My patients seem to have a 
greater appreciation for my 
abilities because of Prescriptive 
Authority Service  
Level 1 
0.28 0.80 7.53 459 <.001 Minor 
Ailment 
 
As displayed in table 4.23. There were statistically significance differences (p < 0.001) 
among respondent’s opinions. Substantial difference (>0.5) were seen for one of the three items: 
Patients’ knowledge about Prescriptive Authority services. 
4.3.5 Participant’s perception of physician’s attitude toward Prescriptive Authority 
Services (Level 1 and Minor Ailment) 
 In the last section of the questionnaire participants were asked five questions each for 
Level 1 and Minor Ailment Prescribing.  
A majority of respondents (311/489, 62.1%) strongly agreed or agreed that the physicians 
they work with appear knowledgeable about what Level 1 prescribing allows them to do (Table 
4.24).  
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Table 4.24: Participant’s perception of physician’s attitude toward prescriptive authority 
services (Level 1 and Minor Ailment) 
 
 
Question 
Type of 
prescribing 
Strongly 
Agree 
n 
(%) 
Agree 
 
n 
(%) 
Neutral 
 
n 
(%) 
Disagree 
 
n 
(%) 
Strongly 
Disagree 
n 
(%) 
Total 
Responses  
n  
(%) 
Mean 
SD 
P 
Value 
The physicians 
that I work with 
appear 
knowledgeable 
about what 
Prescriptive 
Authority 
Services allows 
me to do. 
Level 1 
43 
(8.6) 
268 
(53.5) 
94 
(18.8) 
69 
(13.8) 
15 
(3.0) 
489 
(97.6) 
-0.770 
 0.932 
<.001 
Minor 
Ailment 
7 
(1.4) 
67 
(13.4) 
188 
(37.5) 
149 
(29.7) 
27 
(5.4) 
438 
(87.4) 
The physicians 
that I work with 
appear satisfied 
with the 
Prescriptive 
Authority 
Services I 
provide. 
Level 1 
47 
(9.4) 
318 
(63.5) 
107 
(21.4) 
11 
(2.2) 
2 
(0.4) 
485 
(96.8) 
-0.525 
 0.684 
<.001 
Minor 
Ailment 
10 
(2.0) 
133 
(26.5) 
259 
(51.7) 
21 
(4.2) 
2 
(0.4) 
425 
(84.8) 
The physicians 
that I work with 
seem reluctant 
to support 
Prescriptive 
Authority 
Services 
Level 1 
3 
(0.6) 
27 
(5.4) 
103 
(20.6) 
281 
(56.1) 
64 
(12.8) 
478 
(95.4) 
0.459 
0.737 
<.001 
Minor 
Ailment 
4 
(0.8) 
35 
(7.0) 
224 
(44.7) 
146 
(29.1) 
17 
(3.4) 
426 
(85.0) 
The physicians 
that I work with 
appear to rely 
on me to 
provide 
Prescriptive 
Authority 
Services to 
their patients.  
Level 1 
43 
(8.6) 
211 
(42.1) 
143 
(28.5) 
74 
(14.8) 
14 
(2.8) 
485 
(96.8) 
-0.901 
 1.040 
<.001 
Minor 
Ailment 
4 
(0.8) 
28 
(5.6) 
189 
(37.7) 
185 
(36.9) 
35 
(7.0) 
441 
(88.0) 
The physicians 
that I work with 
seem to have 
greater respect 
for my 
professional 
contribution 
because of 
Prescriptive 
Authority 
Services 
Level 1 
15 
(3.0) 
93 
(18.6) 
280 
(55.9) 
79 
(15.8) 
6 
(1.2) 
473 
(94.4) 
-0.098 
 0.629 
>.001 
Minor 
Ailment 
11 
(2.2) 
48 
(9.6) 
287 
(57.3) 
73 
(14.6) 
7 
(1.4) 
426 
(85.0) 
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A large proportion of respondents were either neutral (188/438, 37.5%) or disagreed 
(149/438, 29.7%) to the same statement about MA Prescribing.  
Participants were then asked whether the physicians they work with appear satisfied with 
the Level 1 service they provide. Almost 73 percent (365/485) of respondents strongly agreed or 
agreed to the statement. In the case of MA Prescribing only 28.5 percent (143/425) of 
respondents strongly agreed or agreed. 
A large proportion of respondents (345/478, 68.9 %) were strongly disagreed or 
disagreed to the statement that the physicians were reluctant to support for Level 1 prescribing 
and 20.6 percent (103/478) were neutral. The same attitude was observed for the same question 
about MA Prescribing with 32.5 percent (163/426) disagreeing with the statement. 
Table 4.25: Paired sample T-Test 
Question Type 
Paired Difference 
t Df 
Sig.  
(2-tailed) Mean Std. D 
The physicians that I work with 
appear knowledgeable about what 
Prescriptive Authority Services 
allows me to do. 
Level 1 
-0.77 0.93 -17.23 434 <.001 
Minor 
Ailment 
The physicians that I work with 
appear satisfied with the 
Prescriptive Authority Services I 
provide. 
Level 1 
-0.52 0.68 -15.78 422 <.001 Minor 
Ailment 
The physicians that I work with 
seem reluctant to support 
Prescriptive Authority Services 
Level 1 
0.46 0.74 12.80 422 <.001 Minor 
Ailment 
The physicians that I work with 
appear to rely on me to provide 
Prescriptive Authority Services to 
their patients. 
Level 1 
-0.90 1.04 -18.03 433 <.001 
Minor 
Ailment 
The physicians that I work with 
seem to have greater respect for 
my professional contribution 
because of Prescriptive Authority 
Services  
Level 1 
-0.10 0.63 -3.19 417 >.001 
Minor 
Ailment 
 
Respondents were asked whether the physicians they work with appear to rely on them to 
provide Level 1 Prescribing to their patients. Two different views of the respondents for two 
different forms of prescribing have been observed in this question. Half of respondents (254/485, 
50.1%) strongly agreed or agreed to the above statement and 28.5 percent (143/485) were 
neutral. A large group of the respondents either disagreed (185/441, 36.9%) or found to be 
neutral (189/441, 37.7%) for the same statement about MA Prescribing.  
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Finally, respondents were asked whether the physicians they work with seem to have 
greater respect for their professional contribution because of Level 1 Prescribing. More than half 
of the respondents (280/473, 55.9%) indicated neutral to the statement. A similar percent 
(287/426, 57.3%) indicated neutral when they were asked the same question about MA 
Prescribing. 
With regard to participant’s perception of physician’s attitude, there were statistical 
significant differences (p < 0.001) observed in four of the five items. Out of which substantial 
difference (>0.5) were seen for three of the four which includes: Physicians knowledge about 
service, Satisfaction with service and rely on pharmacists of this service (Table 4.25).  
Based on the location of the pharmacy, One-way ANOVA revealed statistically 
significant differences between groups in three of the five items out of which one item showed 
significant differences in both the cases (Level 1 and MA) and remaining two in one of each 
Level 1 and MA. Post-hoc analysis later confirmed the differences between groups in only one 
out of three items and only in the case of Level 1 prescribing (Table 4.26). 
Table 4.26: One-way ANOVA (Showing significant differences based on location) 
Question  Sum of Squares Df Mean Square F Sig. 
The physicians that I work 
with appear to rely on me 
to provide Level 1 
prescribing to their patients 
Between Groups 
Within Groups 
Total 
21.359 
413.239 
434.598 
3 
481 
484 
7.120 
0.859 
8.278 0.000 
 
 The item was: The physicians that I work with appear to rely on me to provide Leve1 1 
prescribing services to their patients. Pharmacists working in the rural and small town or small 
cities were more likely to agree with the fact that physicians rely on them to provide Level 1 
prescribing. However, the pharmacists working in medium cities suggested that they neither 
agree nor disagree. 
In order to find the existence of a relationship between variables Chi-square statistical 
tests were performed (Table 4.27). 
No statistical significant differences were found based on respondent’s location and age 
quartiles, location and position, location and sex and location and type of mailing (first or 
second). There were statistical significant difference (p < 0.05) based respondent’s location and 
their method of responding. The test revealed some association between the location of the 
pharmacy and the method of responding (Table 4.27).    
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Table 4.27: Pearson Chi-square test 
Value Df Sig. (2-sided) N 
Location and Age quartile 
8.20 9 0.51 446 
Location and Position 
13.13 6 0.04 498 
Location and Sex 
1.38 3 0.71 498 
Location and type of mailing (first or second) 
0.74 3 0.86 500 
Location and method of responding (mail or online) 
15.97 9 0.001 500 
 
The results of the data analysis along with the responses rate and demographic 
characteristics of respondents are present.   The finding of this study will be discussed, which 
includes respondents’ opinions and views about the series of questions, asked in the survey, 
regarding their practice settings and work environment. 
4.4 Qualitative Results (respondents’ comments) 
In this study, all qualitative data were extracted in the form of respondent’s comments. 
The data were then categorized into four broader themes. Themes were confidence & 
satisfaction, practice environment, patients and physicians.  
Table 4.28: Qualitative Results 
 
 
 
 
  
 
 
 
# 
Comments 
about 
Specific theme # 
Total 
 # 
% 
1 
Confidence & 
Satisfaction 
Confidence 78 
124 
                               
28.0 
 
Less/Not doing it 28 
Satisfaction 18 
2 
   Practice 
Environment 
Time 58 
138 31.1 
Remuneration 30 
Paperwork 28 
Staffing 13 
Pharmacy space and access to blood work 09 
3 Patients 
Satisfaction 36 
103 23.3 
Taking advantage 29 
Knowledge 20 
Mis self-diagnosis 11 
Follow-up 07 
4 Physicians Support 78 78 17.6 
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Total 124 comments were collected under the first theme (Confidence & Satisfaction), 138 
under second (Practice Environment), 103 under third (Patients) and 78 comments were collected 
under the fourth theme (Physicians) (Table 4.28).  
Above, four major themes were sub-divided into specific themes to attain a clear view of 
respondent’s intentions and experiences.  
The First theme (confidence & satisfaction) was categorized into the following three sub-
categories: 
1. Confidence: The comments included in this category were related to pharmacists’ 
confidence in providing PA services. 
Example: My experience with PA over the last 6 months since graduation has been 
great. Once you have done it a couple of times it doesn’t take long at all and it becomes a 
normal pharmacist task-duty we do regularly at our pharmacy. It has also developed 
strong relationships with our patients. I feel that my training to do PA has given me the 
confidence- knowledge that I need to provide this service. PA is an integral start to 
expanding the role of the pharmacist. 
                                                                                                                   (Participant 952). 
2. Less/Not doing it: Comments categorized under this theme were related to whether 
pharmacists were providing less or no PA services to their patients. 
Example: I do not have time to provide minor ailment prescribing because we 
consistently work short staffed and are a busy store. I would feel more confident if I did it 
more often but there is no time in my day. 
                                                                                                                                 (Participant 57). 
3. Satisfaction: Comments under this category were related to pharmacists’ level of 
satisfaction with the services they provide as a part of their expanding scope of practice. 
Example: Its great privilege to provide my patient quick and professional service. I 
enjoyed my experience being a Level 1 and Minor Ailment prescriber. 
                                                                                                                     (Participant 08). 
The Second theme (practice environment) was categorized into five following sub-categories 
1. Time: Comments under this category were related to time management issues. Whether 
or not pharmacists had the time to provide PA services. 
Example: Level 1 prescribing has easily become a routine service in our pharmacy, 
simple to provide, document and bill. Minor ailment prescribing is much more time 
consuming and therefor much more difficult to integrate into the work flow busy-ness 
plus the number of pharmacists available when opportunity arise strongly influence 
if/when these services are provided. 
                                                                                                                   (Participant 104). 
47 
 
2. Remuneration: Reimbursement related comments were included under this particular 
category. Whether or not pharmacists are happy with the reimbursement they get for 
providing PA services. 
Example:  Lack of fair re-imbursement, it takes me at least 5-10 min. to do all the proper 
paperwork. The $6 sometime is just not work even though we always end up doing it 
because for the best interest of patients. But how could it be sustainable when our profit 
keeps going down due to new reforms in pharmacy. 
                                                                                                                   (Participant 290). 
3. Paperwork: Comments containing issues related to paperwork were included in this 
category. 
Example: Pharmacists are expected to do an abundance of paperwork to collect an $ 18 
minor ailment fee. Physicians do minimal paperwork to allow them to prescribe a drug 
for minor ailment. More should be done to decrease the paperwork burden on minor 
ailment prescribing. 
                                                                                                                     (Participant 29). 
4. Staffing: This category contains comments related to staffing issues at the pharmacy that 
pharmacists have pointed out. 
Example: MA prescribing is assuredly more difficult to achieve when combined with 
limited staffing and a busy dispensary. To provide these services we often must attempt to 
do so under considerable time constrain thus generally are only provided when patient 
initiated. Offering of MAP usually occurs during slow periods. Scheduling appointments 
when possible is desirable for time consuming consultations such as acne but not always 
achievable. 
                                                                                                                   (Participant 807). 
5. Pharmacy space and access to blood work: Comments related to private space at the 
pharmacy and access to blood work were included under this category. 
Example: The principle pharmacy I work at, there is no private area to conduct MA 
prescribing, as I am the only pharmacist working during shift (no technician either) this 
would take a lot of time I cannot afford. 
                                                                                                                               (Participant 947). 
The Third theme (Patients) was also categorized into five following sub-categories. 
1. Satisfaction: Comments included under this category were related to patients’ and 
physicians’ satisfaction with PA services provided by the pharmacist. 
Example: Convenient for all patients, reduce wait time for patients by decrease faxing. 
Everyone is much happier. 
                                                                                                                   (Participant 083). 
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2. Taking advantage: Comments included under this category were related to pharmacist’s 
concerns regarding misuse of PA services by patients. 
Example: I just find, especially in my practice, patients to use the Level 1 prescribing as 
a way to delay having to go to the doctor. It’s usually not that they can’t go to the doctor; 
they are just choosing to not make the appointment until they are out of pills, in order to 
try and get an extra month refill. 
                                                                                                                     (Participant 20). 
3. Knowledge: Comments included under this category were related to whether or not 
patients and physicians are knowledgeable about the PA services the pharmacist 
provides. 
Example: I find patients don’t understand what you are allowed to prescribe for minor 
ailments (i.e. always want you to diagnose and prescribe antibiotics because can’t get in 
to see physician in timely fashion). 
                                                                                                                               (Participant 030). 
I have found that the doctors in our area have specifically told their receptionists that 
pharmacists can prescribe anything. This has caused a lot of upset patients when we 
cannot prescribe narcotics, benzos, OTC’s (that have not prescribed b/f), antibiotics 
(because they are not feeling well), etc. 
                                                                                                                   (Participant 389). 
4. Mis self-diagnosis:  Comments included under this category were related to pharmacist’s 
concern about patients’ wrongful self-diagnosis of minor ailment conditions. 
Example: Mis-diagnosis or misleading/ inaccurate answer by patients leading to 
improper product being prescribed (or prescribing when should have referred). 
                                                                                                                   (Participant 427). 
5. Follow-up: Comments included under this category were related to follow-up issues with 
patients that pharmacists as a prescriber face. 
Example: The only concern is follow-up. I have tried to call a couple of patients for a 
follow up after I prescribed something. I either don’t get a call back when I leave a 
message or they never answer. In those situations, you really don’t know whether it 
worked or not or even it really got worse. You counsel people what to expect plus that the 
follow up will happen but sometimes it doesn’t happen at all. 
                                                                                                                   (Participant 651). 
The Fourth and final theme (physicians) was categorized into only one following sub-category. 
1. Support: Comments included under this category were related to whether or not 
pharmacists get support for PA services they provide. 
Example: Male dr. who is 85 years old does not understand our profession and what we 
can do. He has told me that pharmacists know nothing about curing/treating 
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disease/ailments. This has not stopped us from using prescriptive authority. The other dr. 
has been great and has a better understanding. 
                                                                                                                               (Participant 754). 
Due to the large number of comments collected, only a few suitable comments were 
selected to support quantitative findings and answer research questions accurately. 
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5. DISCUSSION 
5.1 Research Question 1 
To what extent has expanded prescriptive authority been integrated into community 
practice? 
The literature shows that in Canada and in other jurisdictions, the ability of pharmacists 
to “prescribe” in a community setting has increased considerably in recent years (Law, Ma, 
Judith, & Sketris, 2012). Their involvement is not limited to urban areas but rural areas as well 
(Phul et al, 2004; CPhA, Sept. 2008). As of 2015, pharmacists in Saskatchewan were eligible to 
prescribe for Level 1 and sixteen Minor Ailment conditions (MedSask, 2015).  
As these new prescribing activities (Level 1 and MA Prescribing) are added to the 
pharmacist’s role, a vast majority of respondents (Pharmacists) indicate that they are highly 
confident (94%) to provide Level 1 prescribing to their patients. They provide Level 1 services to 
three out of every four patients (74.2%) that come to the pharmacy eligible for Level 1 services. 
Respondents have shown enough confidence in providing Level 1 services to the best of their 
ability not only in cities but also in small towns. 
Working in a very small town Level 1 prescribing is very important as sometimes patients 
have hard time getting to the city. Weather can also affect them making their 
appointments. Being able to provide interim supply something a lot of my patients rely 
on. 
                                                                                                                               (Participant 315). 
Along with the high level of confidence some respondents also mentioned that they 
possess enough knowledge to provide Prescriptive Authority Services to the patients on a daily 
basis at the pharmacy they work. 
My experience with PA over the last 6 months since graduation has been great. Once you 
have done it a couple of times it doesn’t take long at all and it becomes a normal 
pharmacist task-duty we do regularly at our pharmacy. It has also developed strong 
relationships with our patients. I feel that my training to do PA has given me the 
confidence- knowledge that I need to provide this service. PA is an integral start to 
expanding the role of the pharmacist. 
                                                                                                                   (Participant 952). 
Although they provide Level 1 prescribing services to almost 75 percent of the patients 
they see, some respondents indicated that there are some potential barriers that get in the way to 
provide Level 1 services to all eligible patients.  
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I feel more confident with renewing prescriptions and find that I can fairly, easily fit that 
into the workflow when needed. Other activities in level 1 prescribing are not used as 
often, so I am less comfortable with those, it would take more time to do.  
                                                                                                                   (Participant 512).                                                                                                                                              
In this study, pharmacists revealed that they provide prescribing services for MA 
conditions to their patients around half of the time (52.5%). However, they report a 75.5 percent 
level of confidence in their MA prescribing abilities. Respondents have also mentioned in their 
comments that they are looking forward to more minor ailments being added in the list so they 
can help more eligible patients. 
Looking forward to increase ailments and increased prescribing level (s) i.e. injections, 
especially flu and hopefully travel vaccines as our patients are lacking accessibility to 
these services.  
                                                                                                                   (Participant 845). 
We should be authorized to extra prescription for drugs that have been used prior to 3 
month period. And also for controlled drug’s antibiotics 
                                                                                                                   (Participant 925). 
Respondents indicated that they only provide MA prescribing services to half of the 
patients they see, and some of them mentioned that there are some potential barriers that need to 
be addressed in order to prescribe to the best of their ability. 
I feel restricted by the flow chart and guidelines and often have to turn patients away and 
refer to dr. when one answer doesn’t line up but I am still confident in my abilities, it 
feels black and white with no room for wiggle.   
                                                                                                                   (Participant 713). 
Pharmacists are primary points of contact for the patient regarding MA prescribing 
services and prescribe for conditions self-diagnosed by the patient (MedSask, 2015). Sometimes 
they are unable to prescribe if they find the self-diagnosis is unreasonable. In this case, they refer 
the patient to a doctor (MedSask, 2015). This potentially hinders their ability to prescribe MA 
versus Level 1.  
For minor ailment we rely on patient self-diagnosis. As the list of ailments grows, I am 
concerned they may jump to conclusions to miss red flags. The forms we fill out with the 
patient do help though! We must all be thorough in our assessment. 
                                                                                                                   (Participant 634).  
Although most of the respondents indicated they are confident in providing MA services, 
some expressed that they sometimes feel a lack of confidence or comfort with MA conditions 
and end up not doing it. 
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Often feel rushed to provide prescriptive authority services I don’t do it often, and  so I 
am uncomfortable with a lot of the minor ailments- do cold sores, allergic rhinitis more 
often so I am more comfortable with these, can get them done faster so tend to do them 
more.  
                                                                                                                   (Participant 316).                                                                                                                              
I do not feel very comfortable and confident in minor ailment prescribing so try to avoid 
doing it.    
                                                                                                                   (Participant 512).                                                                                                                                         
 Several respondents expressed that they do not find enough time to provide MA services 
to their patients as they work at a busy pharmacy. 
I do not have time to provide minor ailment prescribing because we consistently work 
short staffed and are a busy store. I would feel more confident if I did it more often but 
there is no time in my day. 
                                                                                                                                 (Participant 57). 
I don’t do it at all because of the lack of time. 
                                                                                                                               (Participant 105). 
A study by Rosenthal et al. (2011) revealed that pharmacists in Alberta view themselves 
as a dispenser of medication more than a patient centered health care provider. But unlike 
Rosenthal et al., this study suggested that pharmacists are more involved in a patient centered 
care currently than just dispensing medication. Law et al. (2012) also suggested in a study that 
the scope of a pharmacist’s prescribing services has been expanded from their role as a dispenser 
to an independent prescriber. 
I am very glad that we are able to do prescriptive authority. I feel it is extremely 
important for Saskatchewan to keep pace with pharmacy trends across the country. I love 
MA prescribing. I feel prescriptive authority is a must in Saskatchewan and is tailored 
specifically for rural communities that do have gaps in physician contact. 
                                                                                                                   (Participant 594). 
Their responses suggest that if a patient is seeking treatment for a Level 1 condition, most 
of the time they get the necessary treatment from pharmacists. But when it comes to MA 
conditions, they only get treatment half of the time. When symptoms look severe or a pharmacist 
is not able to diagnose it or feels a lack of confidence, patients are referred to the physician. 
Respondents suggested that small refresher courses or seminars on MA prescribing could be a 
big asset in order to increase their confidence levels. 
Would appreciate a “refresher” course via tele health or a live seminar on minor ailment 
prescribing to increase confidence in prescribing this service to patients (e.g. review of 
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differential diagnosis for minor ailments to help decrease concerns ever mis-
diagnosing/liability issues). 
                                                                                                                   (Participant 357). 
Based on response received, it can be assumed that community pharmacists are confident 
in providing these new services to their patients, but as they have indicated, they feel more 
comfortable when they deal with a patient with a Level 1 condition than MA.  
Even though I have taken the MA prescribing, I still feel somewhat hesitant to prescribe. 
I find unless the need is obvious, I am hesitant. I don’t necessarily seek out MA 
opportunities. I am unsure why I feel this way. I assume it is lack of experience and I am 
certain I will feel more confident with practice- I just have to make myself do it. 
                                                                                                                   (Participant 746). 
A recent pilot study by Pharmacy Association of Nova Scotia (PANS) in October 2013 
revealed that there was an increase in the level of confidence of pharmacists in assessing 
patients. It can be projected that the MA prescribing is a recent addition to their practice so they 
may not be familiar with their actual role as a prescriber for MA. Guirguis et al (2011) also 
mentioned that in a similar study that the pharmacists are still unclear about the actual definition 
of “Pharmacist Prescribing”. 
It can be said in the broader context of the health care system in Canada, there is no doubt 
that a patient’s access to medication has improved considerably in the last few decades and non-
urgent patient visits to the physician have decreased (Cooper et al., 2008). This is helping 
physicians to spend more time with patients suffering from chronic conditions or other serious 
health related problems (Cooper et al., 2008). 
Pharmacists have also indicated that since Level 1 and MA prescribing services have 
been integrated into their practice liability has not been an issue that prevents them or affects 
their decision to provide these services to the patients. Only a few pharmacists indicated that 
liability is a concern, as prescriptions are based on self-diagnosis. 
5.2 Research Question 2 
How have the characteristics of the community practice setting affected participation 
by community pharmacists in services associated with expanded prescriptive authority? 
Pharmacists’ response for this research question revealed overall support for prescriptive 
authority along with the challenges they face in day to day practice.  
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Almost all respondents (90%) reported that the pharmacy they work at consistently 
provides Level 1 prescribing to patients but only half (52.9%) provide MA prescribing services. 
This suggests a high level of engagement in the services associated with prescriptive authority 
particularly Level 1 prescribing services.  
 However, the difference in consistency between Level 1 and MA could have been caused 
by a lack of space at some pharmacies, hindering the ability to provide proper patient counseling 
and diagnosis. Hatah et al. (2012) also mentioned that physicians were concerned about 
insufficient space at the pharmacy or unavailability of a private consulting room for pharmacists 
to provide screening, monitoring and prescribing to their patients.  
Being next to a walk-in clinic I don’t find many opportunities to do minor ailment 
prescribing. Being new to this location the pharmacy wasn’t set up to easy do MA 
prescribing as it was at another pharmacy previously worked out.  
                                                                                                                               (Participant 382). 
The principle pharmacy I work at, there is no private area to conduct MA prescribing, as 
I am the only pharmacist working during shift (no technician either) this would take a lot 
of time I cannot afford. 
                                                                                                                               (Participant 947). 
Pharmacists have indicated an overall supportive environment from their managers to 
provide prescriptive authority services. They suggested that their managers are highly supportive 
and appreciate the services they provide as part of their expanded scope of practice (Level 1 and 
MA Prescribing). Lloyd et al. (2010) found less support for these activities from organization 
leaders in their study in the UK. Unlike Lloyd et al, this study indicated tremendous support for 
pharmacists from the managers.   
This study revealed that the paperwork associated with Level 1 prescribing is not a big 
issue to deal with for the pharmacists and this generally doesn’t prevent them to offer Level 1 
prescribing services to their patients; However, half of the respondents also indicted that the 
paperwork associated with MA prescribing sometimes deter them from offering these services. 
This could be due to a difficulty accessing patient records, sharing their information and overall 
inadequate IT infrastructure.  
Pharmacists are expected to do an abundance of paperwork to collect an $ 18 minor 
ailment fee. Physicians do minimal paperwork to allow them to prescribe a drug for 
minor ailment. More should be done to decrease the paperwork burden on minor ailment 
prescribing. 
                                                                                                                     (Participant 29). 
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The required documentation and follow-ups with minor ailment prescribing often deters 
me from prescribing 
                                                                                                                               (Participant 755).  
Researchers in various countries found that these same issues deter pharmacists from 
offering expanded prescribing services.  Cooper et al. (2008) mentioned that several clinical 
practitioners in the UK find the same issues preventing pharmacists to provide Prescriptive 
Authority services, which is later supported by Lloyd et al. (2010). In Australia, Hoti et al (2011) 
also found that pharmacists required more IT resources to integrate new responsibilities 
smoothly. 
This study also revealed two different views of respondents with respect to the priorities 
of other professional duties over Prescriptive Authority services. Slightly more than half of 
respondents indicated that the demands of other professional duties don’t usually take priority 
over Level 1 prescribing. However, almost the same number of respondents indicated other 
professional duties act as a barrier to provide MA prescribing, since MA prescribing is a more 
recent addition to the scope of practice. Respondents previously mentioned that on an average it 
takes around 16 minutes to provide MA prescribing service to a patient. It can be anticipated that 
addition of some new responsibilities could cause additional workload and time pressure.  
Some of the respondents indicated that Prescriptive Authority as a time consuming 
process particularly when they are short of staff at the pharmacy. They highlighted that MA 
prescribing is more time consuming than Level 1which makes their job more difficult. 
Wish we have more time to access lab values but the strain put on us by extra increased 
prescription volume and less staffing makes prescribing more difficult, makes it harder to 
make informed decisions when you are always rushed. 
                                                                                                                     (Participant 80). 
Level 1 prescribing has easily become a routine service in our pharmacy, simple to 
provide, document and bill. Minor ailment prescribing is much more time consuming and 
therefor much more difficult to integrate into the work flow busy-ness plus the number of 
pharmacists available when opportunity arise strongly influence if/when these services 
are provided. 
                                                                                                                   (Participant 104). 
MA prescribing is even more time consuming, honestly, I don’t even offer this option to 
most patients. Realistically, we can only offer it to patients if we are full staffed as it takes 
at least 15 min. to interview patient. 
                                                                                                                   (Participant 204). 
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MA prescribing is time consuming and there is little pharmacist overlap at my store, so I 
find myself recommending OTC products when sometimes the person might be eligible 
for MA prescribing. 
                                                                                                                   (Participant 558). 
MA prescribing is assuredly more difficult to achieve when combined with limited 
staffing and a busy dispensary. To provide these services we often must attempt to do so 
under considerable time constrain thus generally are only provided when patient 
initiated. Offering of MAP usually occurs during slow periods. Scheduling appointments 
when possible is desirable for time consuming consultations such as acne but not always 
achievable. 
                                                                                                                   (Participant 807). 
Cooper et al. (2008) and George et al. (2007) also identified these issues and pharmacists 
dual role as a barrier towards their expanding prescribing authority in Australia which was later 
supported by Hoti et al. (2011). 
With respect to the above research question, respondents have shown strong support to 
the expanding scope of practice and their involvement in it. In terms of consistently providing 
services, managerial support, paperwork and the demands of other professional duties 
respondents indicated overall no issues regarding Level 1 prescribing. In the case of MA 
prescribing the biggest concern that respondents mentioned in their comments is time and 
staffing. There are some issues related to paperwork and the demand of other professional duties 
has also been indicated by the respondents. The reasons are because since MA prescribing has 
been implemented into the pharmacy practice; the number of MA conditions kept increasing. 
Earlier pharmacists were prescribing for seven MA conditions which have now increased to 
more than fifteen (PAS, June 2014).  
At this point I am comfortable with the MA prescribing, but as they are introducing new 
conditions that pharmacists will be expected to prescribe for (GERD, fungal infections, 
hemorrhoids, migraines) I am uneasy. Our education did not go very in-depth about 
physical presentations of certain conditions or that we would have to assess it at 
pharmacy level.  I feel that signs and symptoms of the new conditions may be many “red 
flags” that I will not feel totally comfortable prescribing a medication for. If I am 
expected to, I think our liability insurance should be increased.                      
                                                                                                                   (Participant 701). 
Respondents have also acknowledged that less remuneration or re-imbursement for 
Prescriptive Authority services is an issue that sometime hinders them to provide these services 
to the patients. They have also mentioned that the pharmacists should get paid for these services 
not the employer. 
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Lack of fair re-imbursement, it takes me at least 5-10 min. to do all the proper 
paperwork. The $6 sometime is just not work even though we always end up doing it 
because for the best interest of patients. But how could it be sustainable when our profit 
keeps going down due to new reforms in pharmacy. 
                                                                                                                   (Participant 290). 
Diaper dermatitis- minor ailments- if you go through the whole prescriptive process, 
determine they only need clotrimaderm cream, then you are unable to bill for the minor 
ailment fee. The program would force you to choose ketoderm in order to be billable 
which not a product that I would choose first is. So their category largely remains as just 
OTC counselling.  
                                                                                                                   (Participant 441).                                                                                                                                        
I never thought it would be subject of a quota of how many I do plus how many $ we can 
generate- performance evaluation should not only on this, Also since some prescriptions 
coming to us as to only log at that time not be filled if they have a sig. ever or other 
problem which might be filled for through prescriptive authority it cannot until they are 
filled. Leads some people to log incorrect prescriptions with note to them at time of filling 
but could lead to error as well. (Poor practice driven by $). 
                                                                                                                   (Participant 587). 
Concerned about the companies that are putting goals and numbers of MA and PA that 
one provided by each individual pharmacist, I know of a few companies that are pushing 
these services and putting pressure on individual pharmacists. This will affect their 
performance reviews and bonuses. I personally would have preferred the drug plan to 
reimburse the individual pharmacist for providing these services not the location of 
employment. Not because I want more money but because I believe it would reduce the 
pressure from the organization. The pharmacy would still get the dispensing fee, but the 
individual pharmacist would get the prescribing fee. I believe it would provide more 
incentives for the pharmacists to provide these services and would help to reduce the 
pressure from corporate offices. 
                                                                                                                   (Participant 715). 
Pharmacists are indeed educated, confident, and skilled enough to deal with these 
dramatic changes in their traditional role and also the confidence increases as more you involve 
in the activity so these issues can be resolved as pharmacist proceed toward expertise in MA 
prescribing as they are now in Level 1.  
The above research question has aimed to address the following predictions being made 
in the beginning of this research. 
Ho1:  There is no relationship between various practice characteristics and the 
participation in Level One Prescribing in SK 
Ho2: There is no relationship between various practice characteristics and the 
participation in Minor Ailment Prescribing in SK 
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Both quantitative and qualitative results of this study revealed support for the first 
hypothesis. There were no relationships found between various practice characteristics and the 
participation in Level 1 prescribing. As indicated by the respondents, paperwork generally does 
not affect their participation in Level 1 prescribing services. Both the results also revealed that 
too much paperwork sometime affects pharmacist’s participation in Minor Ailment prescribing 
related services such as: accessing patient records and sharing their information, suggests that 
there is a relationship between various practice characteristics and the participation in Minor 
Ailment prescribing, therefore partially supporting the second hypothesis.   
5.3 Research Question 3 
To what extent has expanded prescriptive authority affected the primary professional 
relationships of community pharmacists? 
5.3.1 Research Question 3a 
How have relations with patients been affected by prescriptive authority? 
A vast majority of respondents supported the notion that the patients are overall satisfied 
with the prescribing services they provide (based on their day to day interaction with the 
patients). However, the number of respondents indicated patients’ satisfaction for Level 1 
prescribing is slightly higher than the MA prescribing. Patient satisfaction with pharmacists 
prescribing indicates the relationship between pharmacists and patient getting better as they are 
interacting more often with each other than earlier.  
Patients overall are appreciate it because sometimes they cannot get an appointment in 
time to see their physician.  
                                                                                                                   (Participant 202). 
In general well received plus highly appreciated by patients. 
                                                                                                                   (Participant 259). 
Stewart et al. (2009) mentioned that since the pharmacist’s scope of practice has been 
expanded, patients are getting quick access to medication, waiting time to see a doctor has also 
reduced, able to have a detailed look of the medication and can have a discussion with the 
pharmacists about their medication. These could be the potential reasons of patients’ satisfaction 
with pharmacist prescribing. 
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PA services an important service to patients. It is convenient and time-saving for them, 
compared to seeing a doctor. It decreases the number of people needing to go to a walk-
in clinic for non-emergency reasons; it saves the health system money. It is rewarding to 
provide PA. The downfall is the small public demand, and the patients don’t pre-book the 
appointment with pharmacists.   
                                                                                                                               (Participant 021). 
 
Convenient for all patients, reduce wait time for patients by decrease faxing. Everyone is 
much happier. 
                                                                                                                   (Participant 083). 
Particularly with minor ailments, patients are so impressed when they get follow-ups 
calls asking how therapy went or if they are going better. 
                                                                                                                   (Participant 435). 
They are very happy that they don't have to wait to see a doctor. 
                                                                                                                    (Participant OL). 
More than half of respondents supported the position that patients seem to have a greater 
appreciation for a pharmacist’s ability to prescribe (Level 1 and MA).  
Patients/customers really appreciate it. 
                                                                                                                   (Participant 247). 
Patients are very complementary. 
                                                                                                                   (Participant 250). 
Safety, quality and continuity of care within health care has improved a lot within a short 
period of time since pharmacists have been granted some prescribing responsibilities (Lloyd et 
al. 2010). According to a study in Australia by Hoti et al. (2011) patients indicated tremendous 
support for pharmacist’s new role as a prescriber and their drug knowledge as well which is quite 
similar to the findings of this study where patients were satisfied and appreciated Prescriptive 
Authority services (Level 1 and MA) by pharmacists. 
Patients are very pleased with the services provided by the pharmacists. 
                                                                                                                   (Participant 707). 
Patient’s improved access to medication could be one of the potential reasons of their 
satisfaction and appreciation for pharmacists Prescriptive Authority. Bassell et al. (2005) and 
Hoti et al. (2011) both reported improved access to medication as a potential reason of patients 
support for expended pharmacists prescribing. 
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 The only concern respondents indicated is “patient knowledge”. As prescriptive 
authority for pharmacists is a recent addition to their practice and MA is more recent, half of the 
respondents strongly disagreed or disagreed with the fact that patients are knowledgeable about 
what MA prescribing services allow pharmacists to do for them. Moreover, around one third 
disagreed or strongly disagreed for Level 1. However, around 40 percent respondents indicated 
support as well for Level 1. 
I find patients don’t understand what you are allowed to prescribe for minor ailments 
(i.e. always want you to diagnose and prescribe antibiotics because can’t get in to see 
physician in timely fashion). 
                                                                                                                               (Participant 030). 
 I have had patients leave the pharmacy angry because they are unaware that they still 
need to meet certain criteria before we can use our prescriptive authority. (I.e. patient 
upset because won’t prescribe valacyclovir when cold sore has already erupted; patient 
angry because won’t extend an expire prescription that has not been filled in 3 months 
and has only been filled 3 times in the last year). As a result, I wouldn’t say my overall 
experience has been very positive. 
                                                                                                                   (Participant 615). 
Many people are not yet aware of which MA we can prescribe for. They often don’t 
realize we can do any of them or they want us to prescribe things we are not authorized 
for ex. Antibiotics. 
                                                                                                                   (Participant 937). 
Participants generally believed that patients are getting benefits of pharmacist prescribing 
by getting easy and rapid access to medication and quick refills, but they are also concerned that 
some patients are using this service as a way to delay having to go to the doctor. Some 
respondents have indicated that patients are using PA as a way to delay having to go to the 
doctor or just expect us to extend refills without seeing a doctor. 
I just find, especially in my practice, patients to use the Level 1 prescribing as a way to 
delay having to go to the doctor. It’s usually not that they can’t go to the doctor; they are 
just choosing to not make the appointment until they are out of pills, in order to try and 
get an extra month refill. 
                                                                                                                     (Participant 20). 
The general feel I have gotten from patients is that I can prescribe anything and that 
coming to me as a replacement to see their M.D. In some instances patients are lazy to 
seeing their M.D.- I am easier to get an “appointment” with. 
                                                                                                                     (Participant 75). 
I feel like people just expect us to extend refills for them. Many patients believe that they 
don’t need to see the doctor ever again for repeats on medications. Can we put refills on 
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minor ailment prescribing? Uploading onto pip plus downloading script onto kroll 
system has some glitches. 
                                                                                                                   (Participant 127). 
Many patients feel this authority just means they do not have to go back to their doctors 
for refills but the doctor wishes them to go back. We have to have extra time explaining 
that when we seem it is appropriate we can extend them an extra month supply but they 
must still return to the doctor for appropriate checkup. 
                                                                                                                   (Participant 169). 
It can be anticipated that the overall relationship between patients and pharmacists is 
healthy and getting healthier day by day as patients are getting benefits of what pharmacists are 
doing for them as prescribers. However, a big part of the patient population is still unable to take 
benefit of pharmacist prescribing, particularly MA, due to the lack of awareness and lack of 
knowledge about pharmacists’ new role. Minor Ailment prescribing services by pharmacist still 
needs to be promoted, by mediums such as: television, newspaper and advertising. A recent pilot 
study by PANS in Nova Scotia (PANS, October 2013) also revealed that MA prescribing needs 
more promotion in order to give benefits of this service to every single patient suffering from a 
MA condition. 
The above research question has aimed to address the following predictions being made 
in the beginning of this research. 
Ho3:  There is no relationship between participation in Level One Prescribing and the 
quality of the pharmacist’s relationship with patients in SK 
Ho4:  There is no relationship between participation in Minor Ailment Prescribing and 
the quality of the pharmacist’s relationship with patients in SK 
Both quantitative and qualitative results of this study generally supports hypothesis three. 
It was found that patient’ knowledge, support and appreciation for the services that pharmacists 
provide as a Level 1 prescriber does not affects pharmacists’ participation in Level 1 prescribing 
and the quality of services they provide. Therefore on a broader intellectual curiosity there was 
no relationship found between pharmacist’s participation in Level 1 prescribing and their 
relationship with patients. 
Both the results of this study also supports hypothesis four. It was found that patient’ 
knowledge, support and appreciation for the services that pharmacists provide as a Minor 
Ailment prescriber does not affect pharmacists’ participation in Minor Ailment prescribing and 
the quality of services they provide. Therefore on a broader intellectual curiosity there was no 
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relationship found between pharmacist’s participation in Minor Ailment prescribing and their 
relationship with patients. 
5.3.2 Research Question 3b 
           How have relations with physicians been affected by prescriptive authority? 
This research question revealed two different views of respondents about the relationship 
between pharmacists and physicians. Overall healthy relations and good interaction with 
physicians has been reported when pharmacists prescribe for Level 1. 
I have had nothing but support from doctors and love this new world of pharmacy. 
                                                                                                                   (Participant 043). 
 However, at the same time, lack of interaction has also been reported when they 
prescribe for MA conditions which could be a potential barrier between the healthy relationships 
of physicians and pharmacists (as MA prescriber).   
For the most part doctors are ok with pharmacist prescribing. However, I have had 
doctors who are unreasonably upset when I have prescribed for certain patients. For ex. 
Patient A is out of his heart pills, dr. does not take fax refills and patient cannot see dr. 
right away. Dr. Calls about 2 weeks later upset that we prescribed heart pills for a 
patient (patient has been on same dose for at least 6 months). I always tell patients to 
follow up with their doctors; even this patient does still have not changed to this day. I 
think barriers like this are still a problem for prescribing today. 
                                                                                                                   (Participant 651). 
Physician support for level 1 prescribing is mixed. The majority are supportive but some 
individuals place restrictions. Ex. 5 day supply only, only on weekends. 
                                                                                                                   (Participant 576). 
Pharmacists have been granted some form of prescribing authority since 2007 in some 
parts of Canada and since then they are continuously involved in some form of prescribing 
activities for the patients initially diagnosed by a physician. That helps in reducing physician’s 
workload and allows them to spend more time with patients having chronic conditions and other 
severe diseases. This could be the reason that a fairly large number of respondents reported that 
physicians are knowledgeable about what pharmacists are doing as a Level 1 prescriber and 
appear to be satisfied with the services that a pharmacist provides to their patients. Lloyd et al. 
(2007) and Cooper et al. (2008) also reported that physicians in the UK had a very supportive 
and optimistic view about pharmacist prescribing where primary diagnosis made by them which 
is later mentioned in a study by Hoti et al. (2011) as well.  
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Conversely, respondents revealed physicians’ lack of knowledge about what they do as a 
MA prescriber and less satisfaction in comparison to Level 1.  
I have found that the doctors in our area have specifically told their receptionists that 
pharmacists can prescribe anything. This has caused a lot of upset patients when we 
cannot prescribe narcotics, benzos, OTC’s (that have not prescribed b/f), antibiotics 
(because they are not feeling well), etc. 
                                                                                                                   (Participant 389). 
I feel that physician offices could decrease work load (if they want to) by having their 
staff knowledgeable and identify when a patient can utilize minor ailment prescribing. 
                                                                                                                   (Participant 537). 
Physician’s offices tend to be uninformed about prescriptive authority. Often patients will 
show up at the pharmacy claiming the physicians often told them that we pharmacists can 
just extend prescriptions. Obviously this is gross over simplification of PA. Even some 
time it is an acute medication the patient is requesting (i.e. antibiotic use for an 
infection). 
                                                                                                        (Participant 894). 
As Level 1 prescribing became a part of their day to day life and physicians are more 
familiar with their role, physicians may find themselves more comfortable with the pharmacist as 
a Level 1 prescriber. However, MA is a more recent addition to the pharmacists’ scope of 
practice and physicians only get into contact with pharmacists when they diagnose a patient 
referred by a pharmacist and that doesn’t happen very frequently.    
 The findings also disclosed that to some extent physicians rely on pharmacists for Level 1 
prescribing services but there was evidence supporting that they depend on pharmacists for MA 
prescribing as well. However, respondents indicated that they get less or no support from 
physicians for the prescribing services they provide. 
Male dr. who is 85 years old does not understand our profession and what we can do. He 
has told me that pharmacists know nothing about curing/treating disease/ailments. This 
has not stopped us from using prescriptive authority. The other dr. has been great and 
has a better understanding. 
                                                                                                                               (Participant 754). 
I find that most of the time, physicians dislike our pharmacy prescribing for their patients 
as they view prescribing medications only to be in the relation of the physicians.   
                                                                                                                               (Participant 980). 
Disappointingly we have had some physicians restrict our ability to provide these 
services to our mutual patients. There has been some physicians’ request that we do not 
provide these services for certain medications, or that we only provide interim supplies 
on weekends and limit the amount of medication we give. 
                                                                                                                                (Participant OL). 
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These findings are not unexpected in terms of physicians support for pharmacist 
prescribing. There are some potential barriers such as:  pharmacist’s lack of confidence, 
inadequate clinical examination skills, and discomfort performing diagnosis which makes 
physicians or primary health care providers to rethink about giving entire patient assessment 
responsibility to the pharmacists.  
I wouldn’t want a patient to delay medical care because I have misdiagnosed their 
ailment. 
                                                                                                                               (Participant 190). 
If any MA condition doesn’t fit the criteria exactly or I seem unsure of diagnosis or 
pushing the limit of when to prescribe, I usually send them to the doctor instead. 
                                                                                                                               (Participant 761). 
Stewart et al. (2009) and Tonna et al. (2007) indicated barriers that make GPs less 
supportive for pharmacist to prescribe independently. A study by Lloyd (2010) also indicated 
less GPs support for pharmacist prescribing. More recently in June 2014, a pharmacy newsletter 
by rxPASSPORT revealed that pharmacist’s lack of confidence on doing MA assessment could 
be a reason which prevent them to become a MA expert. 
The majority of respondents indicated that they are not sure whether the physicians they 
work with respect them for their professional contribution as a prescriptive authority prescriber 
or not. No significant differences have been observed though.  
In the end the findings of this research demonstrate good and healthy relations between 
physicians and pharmacist, which is continuing to improve as the pharmacist’s scope of practice 
is expanding. However, there are some issues regarding pharmacist’s diagnostic skills and their 
lack of confidence in doing MA prescribing needs to be resolved in order to gain complete trust 
from the physicians.  
The above research question has aimed to address the following predictions being made 
in the beginning of this research. 
Ho5:  There is no relationship between participation in Level One Prescribing and the 
quality of the pharmacist’s relationship with physicians in SK 
Ho6:  There is no relationship between participation in Minor Ailment Prescribing and 
the quality of the pharmacist’s relationship with physicians in SK 
Both quantitative and qualitative results of this study generally supports hypothesis five. 
It was found that physician’ knowledge, support and satisfaction for the services that pharmacists 
provide as a Level 1 prescriber does not have a significant effect on  pharmacists’ participation in 
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Level 1 prescribing and the quality of services they provide. Therefore on a broader intellectual 
curiosity there was no relationship found between pharmacist’s participation in Level 1 
prescribing and their relationship with physicians. 
Both the results of this study generally supports hypothesis six. It was found that 
physician’ support and appreciation for the services that pharmacists provide as a Minor Ailment 
prescriber does not have a significant effect on  pharmacists’ participation in Minor Ailment 
prescribing and the quality of services they provide. Therefore on a broader intellectual curiosity 
there was no relationship found between pharmacist’s participation in Minor Ailment prescribing 
and their relationship with physicians. 
5.4 Study Limitations 
 An important limitation of this study was the targeted population. Community 
pharmacists were asked to share their views about what patients and physicians might think 
about the issues examined in the questionnaire. Therefore, results were concluded based on the 
pharmacists’ interpretation of patients’ and physicians’ views. However, this does not have a 
significant impact on the interpretation of data and transparency of overall results. The aim of 
this study was to assess pharmacist’s behavior and perspective regarding challenges they may 
face as a function of their expanding scope of practice. 
The next important limitation of this research was the data collection method. A cross-
sectional study design was used in order to collect data. The cross-sectional study allows 
collecting data at one point in time. Therefore, it restricts the ability to show causality. However, 
this study design allows confirmation of relationships through correlation to acquire an 
understanding of questionnaire issues. 
 Another limitation of this study was the generalization of the findings. Since this research 
was carried out in the province of Saskatchewan, the findings were based on the experiences of 
community pharmacists working exclusively in Saskatchewan. Therefore, the results cannot be 
generalized to the entirety of Canada. This research topic is affecting community pharmacists 
across all the provinces of Canada. Hence, it has created a generalization of respondents’ point of 
view which could be an asset while performing comparative analysis of pharmacists’ experiences 
across Canada. 
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5.5 Conclusions 
 The community pharmacists who participated in this study generally expressed support 
for Prescriptive Authority (both Level 1 and Minor Ailment). Conversely, Level 1 services that 
supported traditional dispensing services were generally more consistently provided, supported, 
and perceived as being valued by others compared to Minor Ailment Prescribing.  
The study suggests that pharmacists are highly confident while serving their patients as a 
prescriber. Moreover, pharmacists indicated that their prescribing services are not only limited 
for patients living in cities but they also provide these services to the patients living in the rural 
areas and small towns in Saskatchewan. Even though pharmacists are highly confident, they still 
fail to provide MA prescribing to half of the eligible patients due to lack of time, limited space 
and improper diagnosis. These issues need to be resolved in order to provide patients full access 
to medication and pharmacists to use their full scope of practice.  
In terms of time and space it is essential that pharmacy managers or owners ensure they 
have a sufficient number of pharmacists, technicians and other working staff at the pharmacy to 
smoothly provide MA prescribing services to their patients. Also managers or owners need to 
make sure that their pharmacy has a small private area for patients so that they can discuss their 
self-diagnosed MA condition with the pharmacist and can get the necessary treatment. 
Pharmacists will also get more opportunities to interact with patients on a daily bases which will 
boost their confidence and increase their diagnostic skills. 
In order to improve pharmacist’s diagnostic skills and give them more confidence some 
refresher courses or live seminars on MA prescribing could be implemented. It may also be 
necessary to provide pharmacists some additional incentives in order to increase their interest 
and involvement in services related to MA prescribing. Or at least pharmacists may get 
reimbursed for the prescribing services they provide instead of their location of employment. 
 The study supports the fact that pharmacists think patients are happy and satisfied with 
many aspects of pharmacist’s new role and seem to have a greater appreciation for the services 
they provide, based on pharmacists opinions. PA is convenient and time saving for the patients 
and decreases their unnecessary visits to the doctor. Nevertheless, the findings suggest that a big 
part of the population is still not completely aware about pharmacist’s new role as MA 
prescriber. This study also suggests that patients need more awareness towards the pharmacist’s 
abilities and their expanded role as a prescriber.  
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 The study revealed generally healthy relations and good interaction between pharmacists 
and physicians as respondents have indicated in their comments that physician’s workload has 
been reduced and they are able to spend time with the patients having severe or chronic disease. 
However, there are some barriers, such as lack of interaction and physician’s knowledge that 
were identified when pharmacists prescribe for MA conditions. Because of these barriers 
pharmacist prescribing ends up getting less support by a physician. These issues can be resolved 
by giving both an opportunity to interact more frequently so that physicians can get to know 
more about pharmacist’s knowledge and capabilities to assess and prescribe as a MA prescriber. 
Moreover, it will help to build more trust in their relationships and most importantly it will give 
time and money saving care to the patients of this province. 
Findings of this research suggest that Level 1 and MA prescribing services resulted in 
positive outcomes for patients, pharmacists as well as physicians. Therefore these services must 
be appreciated, supported and further expanded in this province so that patients can get the full 
benefit of healthcare resources, pharmacists can use their full scope of practice and physicians 
can get more time to spend with patients having chronic diseases.  
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Experience with Prescriptive Authority (PA) Services among  
Saskatchewan Community Pharmacists 
 
 
The purpose of this study is to gather information on your experiences with prescriptive authority 
(Level 1 and Minor Ailment prescribing). For our study, Level 1 prescribing includes activities 
such as: emergency prescription refills, renew/extend prescriptions, changing drug 
dosage/formulation, and therapeutic substitution. Minor Ailments (MA) prescribing includes all 
activities associated with initiating a prescription for a MA condition (i.e., acne, cold sores, 
insect bites, allergic rhinitis, oral ulcers, oral thrush, and diaper rash)   
 
 
Participating in Prescriptive Authority Services: 
 
 
I am confident in my ability to provide Level 1 prescribing services to my patients.  
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
 
Of all the opportunities I have to provide Level 1 prescribing, the percent of which I actually 
provide Level 1 prescribing services (please circle most appropriate percent). 
 
   0 10 20 30 40 50 60 70 80 90  100     
 
 
I am confident in my ability to provide Minor Ailment prescribing services to my patients.  
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
 
 
Of all the opportunities I have to provide Minor Ailment prescribing, the percent of which I 
actually provide Minor Ailment prescribing services (please circle most appropriate percent). 
 
   0 10 20 30 40 50 60 70 80 90  100     
 
On average, in terms of minutes, how much time does it take you to provide Minor Ailment 
prescribing services to a patient for one of the seven listed conditions? 
 
          _______ Minutes 
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Please indicate your level of agreement with the following statements regarding your 
practice setting: 
 
Level 1 Prescribing 
 
My pharmacy consistently provides Level 1 prescribing services to our patients.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
The pharmacy manager supports Level 1 prescribing in this pharmacy.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
Paperwork associated with Level 1 prescribing often deters me from offering these services. 
  
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
The demands of my other professional duties take priority over Level 1 prescribing.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
Minor Ailment Prescribing 
 
My pharmacy consistently provides Minor Ailment (MA) prescribing services to our patients.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
The pharmacy manager supports MA prescribing in this pharmacy.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
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Paperwork associated with MA prescribing often deters me from offering these services  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
The demands of my other professional duties take priority over MA prescribing.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
Please indicate your level of agreement with the following statements regarding your 
perception of patient and physician attitudes toward prescriptive authority services (Level 
1 and Minor Ailment) 
 
Patients and Level 1 Prescribing 
 
My patients seem knowledgeable about what Level 1 prescribing allows me to do for them.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
My patients appear to be satisfied with the Level 1 services I provide.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
My patients seem to have a greater appreciation for my expertise because of Level 1 prescribing  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
 
Patients and Minor Ailment Prescribing 
 
My patients seem knowledgeable about what Minor Ailment (MA) prescribing allows me to do 
for them. 
 Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
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My patients appear satisfied with the MA services I provide.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
My patients seem to have a greater appreciation for my expertise because of MA prescribing.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
 
Physicians and Level 1 Prescribing 
 
The physicians that I work with appear knowledgeable about what Level 1 prescribing allows me 
to do.  
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
The physicians that I work with appear satisfied with the Level 1 services I provide.  
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
The physicians that I work with seem reluctant to support Level 1 prescribing.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
The physicians that I work with appear to rely on me to provide Level 1 prescribing services to 
their patients.  
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
The physicians that I work with seem to have greater respect for my professional contribution 
because of level 1 prescribing.  
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
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Physicians and Minor Ailment Prescribing 
 
The physicians that I work with appear knowledgeable about what Minor Ailment (MA) 
prescribing allows me to do.  
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
The physicians that I work with appear satisfied with the MA services I provide.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
The physicians that I work with seem reluctant to support MA prescribing.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
The physicians that I work with appear to rely on me to provide MA services to their patients.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
The physicians that I work with seem to have greater respect for my professional contribution 
because of MA prescribing.  
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
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The following refer to your level of concern about professional liability associated with 
Level 1 and Minor Ailment prescribing: 
 
Concerns about liability often affect my decision to offer some Level 1 prescribing services.  
 
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
Please indicate any specific issues or concerns you have regarding Level 1 prescribing and 
liability risk: 
 
 
 
 
 
 
 
Concerns about liability often affect my decision to offer some Minor Ailment prescribing 
services.  
Strongly 
Agree 
 
Agree 
 
Neutral 
 
Disagree 
Strongly 
Disagree 
Unable to  
Respond 
□ □ □ □ □              □ 
 
Please indicate any specific issues or concerns you have regarding Minor Ailment prescribing 
and liability risk: 
 
 
 
 
 
 
 
Additional Comments regarding your experience with Prescriptive Authority 
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Demographics 
 
 
Gender: □ Female  □ Male   Age (Years):_________ 
 
 
Current Position (Check all that apply) 
 
□ Staff Pharmacist  □ Manager  □ Associate  □ Owner 
□ Other: ______________________ 
 
 
First three letters of your pharmacy’s postal code: __________ 
 
  
 Pharmacy Type (please select the one that best describes your pharmacy) 
 □ Independent  (fewer than 4 pharmacies □ Banner 
  under the same ownership) □ Grocery Store 
 □ Small Chain (4-10 pharmacies □ Department Store 
  under the same ownership) □ Mass Merchandiser 
 □ Large Chain (more than 10 pharmacies □ Franchise 
  under the same ownership) □ Other (please describe): 
    ___________________________________ 
 
 
The portion below will be separated from the above questionnaire before any responses are put into a database so that your 
responses are not identifiable by any information provided below. 
 
As a follow-up to this survey we are interested in discussing in more detail the subject matter of this questionnaire with those who 
are interested.  The follow-up would consist of a one-on-one telephone conversation with a member of the research team that 
would last approximately 30 minutes.  If you are interested in participating in the second phase of this project, please provide your 
name, city/town, telephone number (including the area code) where you can be reached, and the best local time to contact you 
below. 
Name:  
City/town & province:  
Telephone number:  
Best time to contact you:  
 
 
 
Once responses have been compiled and analyzed, would you like to receive a summary of the findings? 
 Yes via e-mail  
(please provide e-mail address)  
 Yes via postal mail  
(please provide postal address)  
 
Thank you for participating in this study – your time and willingness to share your perspective and 
opinion are greatly appreciated!  
 
86 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
87 
 
 
 
 
 
 
 
 
                                   APPENDIX B 
                                                                Pre-notice Letter 
 
 
 
 
 
 
 
 
 
 
 
88 
 
 
 
 
 
Dear  
 
In approximately one week, you will receive in the mail a request to complete a questionnaire for 
an important research project being conducted at the College of Pharmacy & Nutrition at the 
University of Saskatchewan. For this project, your workplace address was obtained from the 
Saskatchewan College of Pharmacists. 
 
The questionnaire we are asking you to complete seeks to better understand your 
experiences with prescriptive authority services.  Specifically, this province-wide study 
seeks to gain a better understanding of prescriptive authority services as they relate to your 
practice setting and your relationships with your patients and the physicians of your community. 
 
Your participation is important.  However, it is completely voluntary and you do not have to 
complete the questionnaire if you do not wish; you may also refuse to answer individual 
questions.  You may withdraw from the study at any time. Your right to withdraw your data 
from the study will apply until April 30, 2014.  After this, some form of research 
dissemination will have occurred and it will not be possible to withdraw your data. 
 
Should you have any concerns about this research do not hesitate to contact the principal 
investigator (Roy Dobson) by e-mail (roy.dobson@usask.ca), facsimile (306-966-6377) or 
phone (306-966-6363).   
 
Thank you for your time and consideration.  It’s only through people like you, who are willing to 
help in our research, that we are able to gain a greater appreciation for the rewards and 
challenges of the pharmacy practice environment.   
 
Sincerely, 
 
Dr. Roy Dobson, PhD  
Associate Professor of Pharmacy 
College of Pharmacy & Nutrition 
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Re: Community Pharmacists Experience with Prescriptive Authority Services 
 
 
 
The purpose of this study is to increase our understanding of your experiences with the 
provision of prescriptive authority services in Saskatchewan.  The accompanying questionnaire 
includes sections relating to: the extent to which you and your pharmacy provide these services; 
aspects of practice that are seen to support or challenge the delivery of these services; and how 
these services may affect your relationships with your patients and the physicians in your 
community.  The questionnaire should take 10-15 minutes to complete.  If you prefer you can 
complete the questionnaire on-line at: https://www.surveymonkey.com/s/K9PHMLY 
  
Your participation is important.  However, it is completely voluntary and you do not have to 
complete the questionnaire if you do not wish; you may also refuse to answer individual 
questions.  You may withdraw from the study at any time. Your right to withdraw your data 
from the study will apply until April 30, 2014.  After this, some form of research 
dissemination will have occurred and it will not be possible to withdraw your data. 
 
The code number on the questionnaire is designed to give the investigators the ability to 
track questionnaires while keeping your identity strictly confidential.  Once the data collection is 
complete, the list that links code numbers to names will be destroyed.  Only the principal 
investigator (Roy Dobson) and the study co-investigators will have access to the data arising 
from this study.  All information will be stored in secure, locked facilities in the office of the 
principle investigator (Roy Dobson) at the University of Saskatchewan. Results will be 
aggregated to ensure that the identities of individual respondents are safeguarded.  Results will 
be reported in the student-researcher’s thesis, refereed periodicals and at conferences and 
meetings associated with pharmacists and health care organizations. 
 
Should you have any concerns about this research do not hesitate to contact the principal 
investigator (Roy Dobson) by e-mail (roy.dobson@usask.ca), facsimile (306-966-6377) or phone 
(306-966-6363).  You completing and returning this survey constitutes consent for the researchers 
to use the data for the purposes of conducting the study as approved by the University of 
Saskatchewan Behavioural Research Ethics Board (BEH# 11-133).  Should you have any 
questions regarding your rights as a participant in this study you may call the Office of 
Research Services at the University of Saskatchewan (306-966-2084).  Out of town 
participants may call collect.   
 
Sincerely, 
 
Rahul Jain, B Pharm                          Dr. Roy Dobson, BScPharm, MBA, PhD  
Student-researcher and   Principal Investigator and 
MSc Pharmacy Graduate Student  Associate Professor of Pharmacy Administration 
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Re: Community Pharmacists Experience with Prescriptive Authority Services 
 
  
 
You recently received a request to complete a questionnaire regarding your experience with 
prescriptive authority. If you have already completed and returned the questionnaire, thank you.  
If you have not yet completed the questionnaire and intend to do so, we would ask that you 
complete it as soon as possible and to return it in the pre-stamped envelope provided.  If you 
prefer you can complete the questionnaire on-line: https://www.surveymonkey.com/s/K9PHMLY  
 
As you know, the questionnaire we are asking you to complete seeks to increase our 
understanding of your experiences with the delivery of prescriptive authority services in 
Saskatchewan.  The questionnaire should take 10-15 minutes to complete.   
  
Your participation is important.  However, it is completely voluntary and you do not have to 
complete the questionnaire if you do not wish; you may also refuse to answer individual 
questions. You may withdraw from the study at any time. Your right to withdraw your data 
from the study will apply until April 30, 2014.  After this, some form of research 
dissemination will have occurred and it will not be possible to withdraw your data. 
 
Only the principal investigator (Roy Dobson) and the study co-investigators will have access to 
the data arising from this study.  All information will be stored in secure, locked facilities in the 
office of the principal investigator (Roy Dobson) at the University of Saskatchewan. Results will 
be aggregated to ensure that the identities of individual respondents are safeguarded.  Results 
will be reported in the student-researcher’s thesis, refereed periodicals and at conferences and 
meetings associated with pharmacists and health care organizations. 
 
Should you have any concerns about this research do not hesitate to contact the principal 
investigator (Roy Dobson) by e-mail (roy.dobson@usask.ca), facsimile (306-966-6377) or phone 
(306-966-6363).  You completing and returning this survey constitutes consent for the researchers 
to use the data for the purposes of conducting the study as approved by the University of 
Saskatchewan Behavioural Research Ethics Board (BEH# 11-133).  Should you have any 
questions regarding your rights as a participant in this study you may call the Office of 
Research Services at the University of Saskatchewan (306-966-2084).  Out of town 
participants may call collect.   
 
Sincerely, 
 
 
Rahul Jain, B Pharm                          Dr. Roy Dobson, BScPharm, MBA, PhD  
Student-researcher and   Principal Investigator and 
MSc Pharmacy Graduate Student  Associate Professor of Pharmacy Administration 
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Re: Community Pharmacists Experience with Prescriptive Authority Services 
 
 
 
To date, we have not received a completed questionnaire from you, so we are sending you a 
second copy.  If you have already completed and returned the questionnaire, thank you.  If you 
have not yet completed the questionnaire and intend to do so, we would ask that you complete 
it as soon as possible and to return it in the pre-stamped envelope provided. If you prefer you 
can complete the questionnaire on-line: https://www.surveymonkey.com/s/K9PHMLY  
 
As you know, the purpose of this study is to increase our understanding of your experiences 
with the delivery of prescriptive authority services in Saskatchewan.  The questionnaire should 
take 10-15 minutes to complete. Your participation is important; however, it is completely 
voluntary and you do not have to complete the questionnaire if you do not wish; you may also 
refuse to answer individual questions.  You may withdraw from the study at any time. Your right 
to withdraw your data from the study will apply until April 30, 2014.  After this, some form 
of research dissemination will have occurred and it will not be possible to withdraw your data. 
 
The code number on the questionnaire is designed to give the investigators the ability to 
track questionnaires while keeping your identity strictly confidential. Once the data collection is 
complete, the list that links code numbers to names will be destroyed. Only the principal 
investigator (Roy Dobson) and the study co-investigators will have access to the data arising 
from this study.  All information will be stored in secure, locked facilities in the office of the 
principal investigator at the University of Saskatchewan. Results will be aggregated to ensure 
that the identities of individual respondents are safeguarded.  Results will be reported in the 
student-researcher’s thesis, refereed periodicals and at conferences and meetings associated 
with pharmacists and health care organizations. 
 
Should you have any concerns about this research do not hesitate to contact the principal 
investigator (Roy Dobson) by e-mail (roy.dobson@usask.ca), facsimile (306-966-6377) or phone 
(306-966-6363).  You completing and returning this survey constitutes consent for the researchers 
to use the data for the purposes of conducting the study as approved by the University of 
Saskatchewan Behavioural Research Ethics Board (BEH# 11-133).  Should you have any 
questions regarding your rights as a participant in this study you may call the Office of 
Research Services at the University of Saskatchewan (306-966-2084).  Out of town 
participants may call collect.   
 
Sincerely, 
 
 
Rahul Jain, B Pharm                          Dr. Roy Dobson, BScPharm, MBA, PhD  
Student-researcher and   Principal Investigator and 
MSc Pharmacy Graduate Student  Associate Professor of Pharmacy Administration 
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Re: Community Pharmacists Experience with Prescriptive Authority Services 
 
  
 
The response to our study has been very encouraging with approximately 40 percent of 
community pharmacists returning a completed questionnaire. This letter is to advise you that the 
study will be closing soon (post marked April 9, 2014 or sooner), but there is still time to add 
you voice to the study. Simply complete the questionnaire and to return it in the pre-stamped 
envelope previously provided. If you prefer you can complete the questionnaire on-line: 
https://www.surveymonkey.com/s/K9PHMLY  
 
Your participation is important to us.  However, it is completely voluntary and you do not have to 
complete the questionnaire if you do not wish; you may also refuse to answer individual 
questions. You may withdraw from the study at any time. Your right to withdraw your data 
from the study will apply until April 30, 2014.  After this, some form of research 
dissemination will have occurred and it will not be possible to withdraw your data. 
 
Only the principal investigator (Roy Dobson) and the study co-investigators will have access to 
the data arising from this study.  All information will be stored in secure, locked facilities in the 
office of the principal investigator (Roy Dobson) at the University of Saskatchewan. Results will 
be aggregated to ensure that the identities of individual respondents are safeguarded.  Results 
will be reported in the student-researcher’s thesis, refereed periodicals and at conferences and 
meetings associated with pharmacists and health care organizations. 
 
Should you have any concerns about this research do not hesitate to contact the principal 
investigator (Roy Dobson) by e-mail (roy.dobson@usask.ca), facsimile (306-966-6377) or phone 
(306-966-6363).  Completing and returning this questionnaire constitutes consent for the 
researchers to use the data for the purposes of conducting the study as approved by the 
University of Saskatchewan Behavioural Research Ethics Board (BEH# 11-133).  Should you 
have any questions regarding your rights as a participant in this study you may call the 
Office of Research Services at the University of Saskatchewan (306-966-2084).  Out of town 
participants may call collect.   
 
Sincerely, 
 
 
 
Rahul Jain, B Pharm                          Dr. Roy Dobson, BScPharm, MBA, PhD  
Student-researcher and   Principal Investigator and 
MSc Pharmacy Graduate Student  Associate Professor of Pharmacy Administration 
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